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1. Summary 
Malignant melanoma is the most aggressive skin cancer in the world. Currently, melanoma has 
undergone the highest increase in incidence worldwide and is the sixth most common cancer. 
Although melanoma only comprises 4% of all skin cancers, it is responsible for 80% of all skin 
cancer deaths. When patients are diagnosed with stage I or II melanoma, they are often cured 
after surgical excision of the primary lesion. However, if the melanoma is diagnosed with stage 
IV melanoma where distant metastasis has occurred, the one year survival rate is 62%. Thus 
more effective therapies are needed to successfully treat melanoma. Understanding the 
molecular mechanisms that cause melanoma progression will be crucial for developing novel 
drug targets. Melanoma is a heterogeneous cancer, which poses a substantial challenge for 
therapy as multiple subpopulations need to be targeted for effective treatment. Our group has 
proposed the phenotype switching model for melanoma heterogeneity where melanoma cells 
can reversibly switch between states of proliferation and invasion. The two distinct melanoma 
cell phenotypes are named proliferative and invasive and defined by specific gene expression 
signatures and in vitro characteristics.  
The aims of my PhD thesis were to validate the proliferative and invasive gene signatures in a 
larger set of melanoma cell cultures, to investigate the role of SOX10 and SOX9 in melanoma 
progression and to investigate the DNA methylation landscape of melanoma in the context of 
phenotype switching. 
Firstly, we found the proliferative and invasive gene signatures were present in the majority of 
melanoma cell cultures used by many research groups worldwide and the proliferation and 
invasive capacities predicted by the gene signature of some of these melanoma cell cultures 
were functionally validated by in vitro experiments. 
Secondly, we found SOX9 and SOX10 to be antagonistic regulators of each other in melanoma 
development in vitro and in vivo. The Tyr::NrasQ61K mouse is hyperpigmented and has multiple 
melanocytic naevi. SOX10 haploinsuffiency in the Tyr::NrasQ61K mouse results in normal 
pigmentation and no naevi. SOX9 deletion in a Tyr::NrasQ61K SOX10fl/- mouse restores 
hyperpigmentation and naevi formation. Overexpression of SOX9 in melanoma cells 
downregulates SOX10 and knockdown of SOX10 upregulates SOX9. In melanoma patients, 
high SOX10 expression correlates with poor survival. Taken together, the loss of SOX10 
upregulates SOX9, consequently inhibiting melanoma tumor formation. 
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Thirdly, characterization of the DNA methylation landscape of the proliferative and invasive 
phenotypes revealed SOX9 as a target of DNA hypermethylation in the proliferative phenotype. 
Overexpression of SOX9 can reduces proliferation but induces invasion in melanoma cells and 
increase metastasis in mice. In melanoma patients, high SOX9 expression correlates with poor 
patient prognosis. Taken together, although SOX9 reduces the growth of the tumor, it allows the 
tumor cells to become migratory which lead to poor patient survival. 
In summary, phenotype switching is an important mechanism for melanoma development. 
Genes that define the phenotypes like SOX10 and SOX9 have functional roles in driving 
disease progression and could be potential targets for future melanoma therapy. 
2. Zusammenfassung 
Das maligne Melanom ist der aggressivste Hautkrebs weltweit. Aktuell ist das Melanom die 
Krebsart mit den meisten Neuerkrankungen und damit das sechst-häufigste Krebsleiden. 
Obwohl nur etwa 4% aller Hautkrebsfälle als Melanom diagnostiziert werden, sind 80% aller 
hautkrebs-assoziierten Todesfälle Melanompatienten. Solange Patienten mit Stadium I oder II 
ihrer Erkrankung diagnostiziert werden, kann eine Heilung durch eine vollständige operative 
Entfernung des Tumors erfolgen. Befindet sich die Krebserkrankung aber schon im Stadium IV, 
indem sich bereits Fernmetastasen gebildet haben, beträgt die Überlebenschance im ersten 
Jahr gerade mal 62%. Aus diesem Grund ist es dringend nötig, effektivere 
Therapiemöglichkeiten für Patienten mit metastasierten Melanomen zu schaffen. Hierbei ist das 
Verständnis der molekularen Mechanismen der Melanommetastasierung essentiell um neue 
Therapieansätze zu schaffen. 
Die momentane Herausforderung für einen effizienten Therapieansatz ist die Heterogenität 
verschiedener Zellpopulationen innerhalb eines Tumors zu eliminieren. Unsere Arbeitsgruppe 
hat hierzu das „phenotype-switching“ Modell eingeführt, welches vorschlägt, dass 
Melanomzellen reversibel zwischen zwei Zuständen von Proliferation oder Invasion wechseln 
können, was zu der beobachteten Heterogenität beiträgt. Ob eine Tumorzelle proliferativ oder 
invasiv ist wird durch bestimmte Genexperessionsmuster und das in vitro Verhalten der 
Melanomzellen bestimmt. 
Die Ziele der vorliegenden Doktorarbeit sind die Validierung der proliferativen und invasiven 
Genexperessionsmuster in einer grösseren Anzahl Melanomzelllinien, das Erforschen der Rolle 
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der Proteinfaktoren SOX10 und SOX9 bei der Melanomprogression, sowie das Erforschen der 
DNA-Methylierungsmuster im Kontext des „phenotype-switching“ Modells. 
Erstens fanden wir die proliferativen, sowie invasiven Genexpressionsmuster in dem grössten 
Teil der getesteten Melanom-Zellkulturen aus verschiedenen Forschungslabors weltweit und 
konnten diese Genexpressionsmuster mit dem in vitro Verhalten von Proliferativen, sowie 
invasiven Zellkulturen funktionell korrelieren.  
Zweitens, wurde gefunden, dass SOX9 und SOX10 antagonistische Regulatoren während der 
Entwicklung des Melanoms sind, sowohl in vitro als auch in vivo. Die gentechnisch veränderten 
Mäuse Tyr::NrasQ61K sind hyperpigmentiert und entwickeln multiple melanozytäre Läsionen. 
SOX10 Haploinsuffizienz in Tyr::NrasQ61K gentechnisch veränderten Mäusen resultiert in 
normaler Pigmentation und keinerlei Entwicklung von melanozytären Läsionen. Die Deletion 
von SOX9 in Tyr::NrasQ61K SOX10fl/- gentechnisch veränderten Mäusen hingegen zeigt wieder 
den Ursprünglichen Phänotyp mit Hyperpigmentation und der Entwicklung von melanozytären 
Läsionen. Die Überexpression von SOX9 in Melanom-Zellkulturen verringert die Expression von 
SOX10 und der Verlust von SOX10 erhöht die Expression von SOX9. In Expressionsdaten von 
Melanompatienten korreliert eine hohe SOX10 Expression in den Tumoren mit geringeren 
Überlebenschancen. Zusammenfassend kann gesagt werden, dass der Verlust von SOX10 
Proteinexpression dazu führt, dass SOX9 Proteine eine erhöhte Expression erreichen und somit 
die Tumorbildung inhibieren. 
Drittens, zeigte die Charakterisierung von DNA-Methylierungsmustern der proliferativen und 
invasiven Phänotypen , dass der DNA Abschnitt für das SOX9 Gen hypermethyliert ist, jedoch 
ausschliesslich in der DNA von proliferativen Melanomzellen. Die Überexpression von SOX9 
reduziert die Proliferationsrate, aber Erhöht auch die Invasivität der Melanomzellen und die 
Metastasenformierung in Mäusen. Bei Melanompatienten korreliert hohe SOX9 Expression in 
den Tumoren mit schlechter Prognose. Obwohl SOX9 die Wachstumsrate von Tumoren 
verlangsamt, erhöht es auf der anderen Seite die Migration der Krebszellen, und das führt dann 
zu einer schlechteren Prognose für die Patienten. 
Zusammenfassend lässt sich sagen, dass das „phenotype-switching“ Modell ein wichtiger 
Mechanismus für die Melanomentwicklung ist. Gene, welche die Zellphänotypen prägen, wie 
die hier beschriebenen Faktoren SOX10 und SOX9, haben funktionelle Aufgaben in der 
Krankheitsentwicklung und können somit als potentielle Zielmoleküle für zukünftige 
Melanomtherapien betrachtet werden.  
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3. Introduction 
Melanoma epidemiology 
Cutaneous melanoma arises from transformed melanocytes which reside in the basal layer of 
the epidermis and are derived from the neural crest during development (1). It is the most fatal 
skin cancer, although it only comprises about 5-7% of skin malignancies it causes up to 75% of 
skin cancer related deaths due to its capacity to rapidly metastasize (2). The incidence of 
cutaneous melanoma is rising faster than any other solid tumor. In Switzerland, the incidence of 
melanoma is the third highest in the world (20.3 cases per 100, 000 people) after Australia (34.9 
cases per 100,000 people) and New Zealand (35.8 cases per 100,000 people) (3). Although the 
5 year survival is quite high for primary melanomas at (i.e. 98%), once the melanoma has 
metastasized the 5 year survival rate is only 16.1% (4).  
 
Melanoma staging 
Melanoma is staged according to the guidelines set by the American Joint Committee on 
Cancer (5). The TNM staging system is used to determine the size of the tumor (T) as 
determined by Breslow’s thickness and ulceration, the presence or absence of regional 
lymphatic metastases with the number of lymph nodes involved (N), and the presence or 
absence of distant metastases (M). This score provides the TNM staging for the melanoma as 
detailed in Table 1. 
Table 1: The 2009 staging system for cutaneous melanoma according to the AJCC. 
Classification Thickness (mm) Ulceration Status/Mitoses 
T     
     Tis NA NA 
     T1 ≤1.00 a: Without ulceration and mitosis <1/mm2 
b: With ulceration or mitoses ≥1/mm2 
     T2 1.01–2.00 a: Without ulceration 
b: With ulceration 
     T3 2.01–4.00 a: Without ulceration 
b: With ulceration 
     T4 >4.00 a: Without ulceration 
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b: With ulceration 
N No. of Metastatic Nodes Nodal Metastatic Burden 
     N0 0 NA 
     N1 1 a: Micrometastasis* 
b: Macrometastasis† 
     N2 2–3 a: Micrometastasis* 
b: Macrometastasis† 
c: In transit metastases/satellites without 
metastatic nodes 
     N3 4+ metastatic nodes, or matted 
nodes, or in transit 
metastases/satellites with 
metastatic nodes 
  
M Site Serum LDH 
     M0 No distant metastases NA 
     M1a Distant skin, subcutaneous, or 
nodal metastases 
Normal 
     M1b Lung metastases Normal 
     M1c All other visceral metastases Normal 
  Any distant metastasis Elevated 
Abbreviations: NA, not applicable; LDH, lactate dehydrogenase. 
*Micrometastases are diagnosed after sentinel lymph node biopsy. 
†Macrometastases are defined as clinically detectable nodal metastases confirmed 
pathologically 
 
Melanoma risk factors 
The main environmental factor risk factor is ultraviolet (UV) light exposure, which is causally 
related to melanoma risk. UV light is composed of UVA and UVB wavelengths. UVA is defined 
as waves ranging 400 to 315 nm and UVB is defined as waves ranging 315 to 280 nm. UVA are 
less energetic than UVB and are not known to cause direct DNA damage but can cause indirect 
DNA damage by free radical and reactive oxygen species generation (6-8). UVB is known to 
cause C-T or G-A transitions which result in pyrimidine dimers that lead to mutated proteins. 
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This UVB damage signature can be seen by genome sequencing studies in melanoma (9, 10). 
These C to T transition occur in many tumor suppressor genes including CDKN2A, PTEN and 
TP53 (see Molecular Subtypes) and a smaller portion of them occur in oncogenes such as 
RAC1, STK19, FBXW7, IDH1 and TERT (11). In fact, melanoma is the cancer with the highest 
mutation rate where C to T transitions predominate in the mutation distribution (12). UVB 
radiation has been demonstrated to accelerate melanomagenesis and produce UVB damage 
signature mutations in a BRAF V600E mutant melanoma mouse model (13). 
Skin pigmentation is also a known risk factor for developing melanoma. The Fitzpatrick skin type 
classification defines 6 skin phenotypes based on their response to sun exposure (14). There is 
an inverse correlation with melanoma risk and skin type from fair skin to pigmented skin (Figure 
1) 
 
Figure 1 – Melanoma risk vs skin type. Fitzpatrick classification of skin type with correlation to 
pigmentation, response to UV and melanoma risk. From D’Orazio, JA 2013 
 
It has been estimated that 5-10% of all cutaneous melanomas occurs in families with hereditary 
melanoma predisposition (15). Point mutations in the CDKN2A locus account for 20-40% of 
these familial melanoma cases (16-19). The CDKN2A locus encodes for two tumor 
suppressors, p14ARF and p16INK4A, which regulate the p53 and retinoblastoma (RB) pathways 
respectively. Activating point mutations in cyclin-dependent kinase 4 (CDK4) are also known to 
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cause familial melanoma, but these are much rarer with only 17 cases reported (20, 21). CDK4 
is a gene required for cell cycle progression and activating mutations allow for uninhibited cell 
growth. Germline mutations in the promoter region of the telomerase reverse transcriptase gene 
(TERT) were found to be associated with familial melanoma and interestingly somatic mutations 
in the same region are also found frequently in sporadic melanoma cases (22, 23). These 
mutations increase the transcription of TERT. And most recently, germline mutations in the 
gene protection of telomeres 1 (POT1) were identified as increasing susceptibility for familial 
melanoma (24, 25). POT1 mutations were found in about 4% of familial melanoma cases that 
lacked CDKN2A and CDK4 mutations.  
Mutations in pigmentation genes like melanocortin 1 receptor (MC1R) and microphthalmia-
associated transcription factor (MITF) have also been associated with familial melanoma 
independent of their function in skin pigmentation. MC1R is a G protein-coupled receptor that 
binds to melanocortins such as melanocyte-stimulating hormone (MSH) and activates MITF for 
melanin production. Partial loss of function mutations are associated with phototype 1: fair skin, 
red hair and poor tanning and also associated with increased risk of developing melanoma 
independent of sun exposure (26, 27). MITF is an essential transcription factor required for 
activation of many genes which lead to melanocyte differentiation and pigmentation. A point 
mutation was found to impair normal SUMOylation of MITF leading to increased activation of 
MITF and increased risk of developing melanoma (28).  
Taken together, environmental factors, skin phenotype and genetic factors all contribute to an 
individual’s risk of developing melanoma.  
 
Clinical Subtypes 
There are four major clinical subtypes of primary cutaneous melanoma: superficial spreading 
melanoma, nodular melanoma, lentigo maligna melanoma, and acral lentiginous melanoma. 
These four subtypes are distinguished by their histologic growth pattern, anatomic site, and 
degree of sun damage. Whether melanoma subtypes influence the overall prognosis remains 
controversial.  
Superficial spreading melanoma accounts for about 70% of cutaneous melanoma and is the 
most common subtype in adults aged 30-50 years. It is most common on the trunk in men and 
women and on the legs of women. Irregular asymmetric borders are characteristic. 
9 
 
Histologically, it is characterized by pagetoid scatter of atypical melanocytes within the 
epidermis.  
Nodular melanoma accounts for about 15-30% of cutaneous melanoma and is most commonly 
seen on the legs and trunk of men and women. Rapid growth occurs over weeks to months and 
it is responsible for most thick melanomas.  
Lentigo maligna melanoma is a pigmented slow growing macule often arising from chronic sun 
exposed skin. The in-situ precursor lesion, lentigo maligna, is usually a greater than 1 cm 
diameter pigmented macule that has been present for a minimum of 10-15 years. Progression 
to lentigo maligna melanoma occurs upon dermal invasion and is characterized by the 
development of raised blue-black nodules.  
Acral lentiginous melanoma is the least common clinical subtype in Caucasian individuals and 
the most common in African, Asian, and Hispanic individuals. It occurs on the palms, soles, and 
beneath the nail plate. It presents with a flat phase with similar appearances and changes to 
superficial spreading melanoma.  
 
Melanocytes and melanoma 
Melanocytes are pigment producing cells located at the basal layer of the epidermis and are 
derived from neural crest stem cells (NCSCs) during embryonic development. Initially NCSCs 
are multipotent and as they migrate throughout the embryo their multipotent potential gradually 
becomes lineage restricted due to the micro-environmental influences encountered during their 
journey.  They eventually become a specific differentiated cell depending on their final location 
which includes a plethora of different cell types such as glia, neurons, smooth muscle cells, 
adipocytes, osteoblasts, chondrocytes, and melanocytes.  A number of transcription factors 
regulate the neural crest migration and differentiation process, one of which is sex-determining 
region Y (SRY)-box 10 (SOX10). SOX10 is essential for these cells to maintain their 
multipotency (29). Homozygous deletion of SOX10 in mice leads to embryonic lethality, 
whereas SOX10 haploinsuffiency causes aganglionosis of the colon and pigmentation defects 
(30-33).   
In the adult body, NCSC subpopulations still exist in location specific stem cell niches and the 
skin has one of these stem cell compartments which contain a subpopulation of NCSCs called 
melanocyte stem cells (34-36). Melanocyte stem cells are located in the hair follicle and will 
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differentiate and produce pigment for the hair during successive rounds of hair growth (37). 
SOX10 is expressed throughout all stages of the melanocyte lineage (38) and has two essential 
roles in the melanocytic lineage; firstly, to establish and maintain of the melanocyte stem cell 
population and secondly, to regulate the production of pigment from melanocytes (39). SOX10 
regulates many targets during neural crest development including MITF which is considered the 
master regulator for normal melanocyte development (40, 41). SOX10 expression has been 
detected at varying levels in melanoma by immunohistochemistry (42, 43) and high SOX10 
expression is correlated with poor prognosis (44, 45). A decrease in SOX10 expression results 
in increased p21 and p27 expression, inhibitors of cyclin-dependent kinases (CDKs), and 
subsequently causes cell cycle arrest (46).  In vivo, SOX10 haploinsufficiency in NrasQ61K and 
Grm1Tg mice reduce melanoma formation. NRAS and GRM1 activate the mitogen activated 
protein kinase (MAPK) and phosphatidylinositol-3-kinase (PI3K) signaling pathways, which are 
important pathways for melanomagenesis (46, 47). From these studies, it seems that not only 
SOX10 is important for normal melanocyte function but aberrant expression of SOX10 can 
cause melanoma. 
 
Molecular Subtypes 
The mutational landscape of melanoma has been elucidated in several large exome sequencing 
studies (9-11) and has allowed the identification of many driver mutations and supporting 
mutations. This led to the molecular characterization of melanoma driven by specific oncogenes 
in the MAPK pathway.    
BRAF is the most common gene mutated in melanoma (35% to 45%) (48). BRAF is one of the 
kinases in the MAPK kinase cascade. The four main effectors of this pathway are NRAS, BRAS, 
MEK and ERK. The frequency of the NRAS mutation is also quite high (20-30%) and is mutually 
exclusive with BRAF. Thus MAPK mutations comprise about 55-75% of the driver mutations in 
melanoma. The most common mutation in BRAF results in a valine to glutamic acid substitution 
at codon 600 (BRAFV600E) allowing BRAF kinase activity to be constitutively active. The most 
common mutations in NRAS occur at glutamine 61 (NRASQ61K, 65%) and glycine 12 (NRASG12V, 
35%) which prevent efficient hydrolysis of RAS GTP to RAS GDP (49, 50), thus allowing 
constitutive activity of RAS GTP. Interestingly, the BRAF and NRAS mutations are not UVR 
induced mutations suggesting a UVR independent mechanism for melanoma initiation. In the 
remaining population of melanomas that do not have oncogenic BRAF or NRAS mutations, 
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about 10% have inactivating mutations in neurofibromin (NF1), a negative regulator of Ras. NF1 
mutations have been seen in conjunction with BRAF exon 11 activating mutations and in BRAF 
and NRAS double wild-type melanomas (51, 52). The high frequency of mutations leading to 
aberrant MAPK activation indicates this signaling cascade to be the main pathway melanoma 
utilizes for development. Activated NRAS can also signal through the PI3K pathway, which also 
promotes proliferation and survival. 
c-KIT is the receptor tyrosine kinase for stem cell factor (SCF) upstream of NRAS. Mutations in 
exons 11 and 13 comprise about 85% of all c-KIT mutations (53). Activating mutations in c-KIT 
or amplification lead to activation of the MAPK and PI3K pathways. c-KIT mutations are most 
common in mucosal melanomas, acral lentiginous melanomas and melanomas arising from 
chronically sun damaged skin (54, 55).  
Point mutations are not the only genetic aberrations seen in melanoma, copy-number gains and 
losses have also been extensively characterized. AKT3, a downstream effector in the PI3K 
pathway, has been shown to be amplified in a fraction of melanomas and functionally leads to 
the development of melanoma (56).  PTEN, a well-known tumor suppressor, is silenced in about 
50-60% of melanomas most commonly by focal deletion or allelic loss (9, 57-59). Loss of PTEN 
leads to constitutive activation of the PI3K pathway and is often associated with the BRAFV600E 
mutation (60). In contrast to familial melanoma where CDKN2A is inactivated by point 
mutations, in sporadic melanoma CDKN2A is silenced by allelic loss or focal deletion which 
occurs in about 20-40% of all melanoma cases (57, 61). MITF, a gene mutated in familial 
melanoma, also has the same point mutation in sporadic melanoma (28). In addition to the point 
mutation, amplification of MITF occurs in about 20% of melanoma leading to aberrant MITF 
activity (62). MITF is also a target of the MAPK pathway, thus highlighting the importance of 
MITF as central node in melanoma development.  
In summary, the molecular landscape of melanoma is very diverse and heterogeneous (Figure 
2). Multiple oncogenic driver mutations can initiate melanoma and the diverse array of molecular 
aberrations that support the driver mutation can create a complex situation for treatment. 
Although most of the focus in the past decade has been on the MAPK pathway for drug 
development, the recent surge in whole exome and genome studies have provided many 
potential therapeutic targets in alternate signaling pathways. 
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 Figure 2. Signaling pathways involved in melanoma development. Genes highlighted in red are known to 
have genetic aberrations in melanoma. The majority of aberrations are located in the MAPK pathway 
consisting of c-KIT, NRAS, NF1, BRAF, MEK and ERK which activate MITF among other transcription 
factors that lead to cell growth and survival. MC1R can activate MITF independent of MAPK signaling. 
The PI3K pathway complements the MAPK pathway by also inducing proliferation and survival signals . 
(Lo JA, 2014) 
 
Melanoma therapy 
In recent years, several landmark clinical trials for targeted-therapy have boosted the patient 
survival rate but many patients still relapse after targeted therapy (63). The first targeted therapy 
to display significant benefit over standard chemotherapy was vermurafenib, a small molecule 
inhibitor specifically targeting the BRAF V600E mutation. In a phase III trial, the overall 
response rate of 48% was seen in the vermurafenib group compared to the dacarbazine group, 
which only had an overall response rate of 5% (64). That led to FDA approval in 2011. 
Dabrafenib, another BRAFV600E inhibitor with similar results was approved in 2013 (65). Despite 
the promising results from the clinical trials of these inhibitors, only about half of the patients 
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with a BRAFV600E mutation benefit from targeted therapy and patients that do benefit initially, 
inevitably relapse, resulting in a median progression free survival time of 5 to 7 months. Thus, 
many groups have been investigating the intrinsic and acquired resistance mechanisms to 
BRAFV600E inhibitor therapy.  
Multiple mechanisms of acquired resistance have been elucidated and most involve reactivation 
of the MAPK pathway. Activation of receptor tyrosine kinases like Insulin-like growth factor IR 
(IGF-IR) (66), platelet-derived growth factor receptor B (PDGFRB) (67), and epidermal growth 
factor receptor (EGFR) (68) have all been shown to confer resistance to BRAF inhibitor therapy. 
The therapy can fail due to BRAF splice variants where a truncated form of BRAFV600E is 
expressed and can dimerize with full length BRAFV600E leading to activation of MEK (69). Also 
BRAFV600E amplification was found to confer resistance to BRAFV600E therapy (70). Downstream 
of BRAF, MEK1 and MEK2 activating mutations have been detected in the resistant tumors (71, 
72). Up-regulation of COT1/MAP3K8, an activator of MEK has also been elucidated (73). NRAS 
mutation and loss of NF1 (67, 74) have also been detected and they activate the PI3K pathway 
in conjunction to the MAPK pathway. The surrounding microenvironment can release stromal-
derived hepatocyte growth factor and activate the MET tyrosine kinase receptor on melanoma 
cells to signal through the MAPK and PI3K pathways to bypass BRAFV600E inhibitor treatment 
(75). To add another level of complexity of acquired resistance, intratumoral heterogeneity was 
observed in some patients; Van Allen et al. reported that multiple independent resistance 
mechanisms described above were observed within the same resistant tumor biopsy (72). 
Given the numerous intricate mechanisms that a tumor can employ to become resistant, 
multiple drug combinations targeting the MAPK and PI3K pathway might be necessary to 
prevent resistance.  
Intrinsic resistance mechanisms to the BRAFV600E inhibitor include aberrant activation of the 
PI3K pathway, namely AKT3 amplification and loss of PTEN (76, 77), increased CDK4 
expression (78), NF1 loss (51, 52, 74), activated MET and SRC signaling (79), and stromal 
secretion of HGF that activates MET on melanoma cells (75). Recently, phenotype switching 
has also been shown to be an intrinsic resistance mechanism to BRAFV600E inhibitor therapy 
(80). Briefly, phenotype switching is a model for melanoma that describes two cell states, one 
with MITF expression and one with MITF low expression regardless to mutation status. 
BRAFV600E mutant cells with high MITF were more responsive to inhibitor treatment than to cells 
with low MITF. These studies suggest that molecular screening for these intrinsic resistance 
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mechanisms could be beneficial in BRAFV600E patients to determine if they will respond to 
BRAFV600E inhibitor therapy. 
Immunotherapy, which involves the blockade of immune checkpoint inhibition, has also been 
quite successful in the treatment of melanoma in the past couple of years. T cell activation 
requires T cell receptor recognition of an antigen presented on the surface on an antigen 
presenting cell (APC) and a second costimulation step that is mediated by either a stimulatory 
or inhibitory receptor-ligand pairs known as immune checkpoints. Cytotoxic T lymphocyte 
antigen-4 (CTLA4) is an inhibitory molecule expressed on T cells and inhibits binding of CD28 
on T cells to B7 proteins on APCs thus weakening the costimulation of T cells and CTLA4 is 
also expressed by melanoma cells (81). Ipilimumab, an anti-CTLA4 antibody, was FDA 
approved in 2011 from a phase III trial which showed an overall response rate of 11% in the 
ipilimumab group compared to the dacarbazine group of 5%; although the response was limited, 
it was quite durable (82). Most recently, pembrolizumab, an anti-PD-1 antibody, was FDA 
approved in 2014 from a promising phase I study which showed an overall response rate of 
52% and less autoimmune toxicities compared to ipilimumab (83, 84).  PD-1, like CTLA4, is also 
an inhibitory receptor which binds to PD-L1 and PD-L2 and melanomas express PD-L1 (85). 
One of the large benefits of immunotherapy over targeted therapy is all patients regardless of 
genetic background are eligible for treatment. Resistance mechanisms to immunotherapy are 
not as well elucidated as targeted therapy, but a few have been explored. Phenotype switching 
has also been suggested as a resistance mechanism to immunotherapy. Adoptive T cell 
transfer (ACT) is an immunotherapy that involves selection for cytotoxic T cells that target 
melanocytic antigens. In an ACT murine model, melanoma cells were seen to switch between a 
differentiated and a dedifferentiated phenotype in response to T-cell driven inflammatory 
signaling molecules, like tumor necrosis factor alpha (TNF-α), in a reversible manner inducing 
resistance to ACT therapy (86). This method would suggest that cytotoxic T cells that target the 
dedifferentiated phenotype could be beneficial to prevent resistance. 
 
Phenotype Switching 
Phenotype switching has been the subject of intense investigation and many groups have 
contributed to the characterization of the proliferative and invasive phenotypes seen in 
melanoma (Figure 3). The proliferative phenotype is classified by melanocytic gene expression 
such as MITF, Melan-A, and SOX10. The invasive phenotype is classified by mesenchymal 
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gene expression such as Wnt5A, transforming growth factor beta (TGFB) and fibroblast growth 
factor 2 (FGF2). MITF is known to be the master regulator of melanocyte development and is 
generally overexpressed in melanoma (87). MITF is essential for melanoma cell proliferation 
and melanoma cells with low MITF expression have decreased proliferation but increased 
invasion (88-93). The low MITF expressing cells have many mesenchymal signaling pathways 
upregulated like the TGFB pathway (94, 95), the sonic hedgehog (SHH) pathway (91), the Brn-
2/NOTCH pathway (92, 93), the AXL/NF-kB pathway (80) and the Wnt/B-catenin pathway (96, 
97). Both MITF high and MITF low populations give rise to tumors in immunocompromised 
mice, although the MITF low populations give rise to larger and faster growing tumors 
suggesting the MITF low population to be more tumorigenic (89). Inhibition of TGFB signaling by 
SMAD7 overexpression (98) and by a TBRI inhibitor SD-208 (99) reduces melanoma bone 
metastases. GLI2, a transcription factor activated by sonic hedgehog signaling, inhibits MITF 
expression and is required for invasion in vitro and in vivo (95, 100). The transcription factor 
Brn-2 also inhibits MITF expression and activates NOTCH to induce invasion of melanoma cells 
(93), and intra-vital imaging of melanoma tumors showed that when melanoma cells become 
motile, they increase BRN2 expression and when melanoma cells become stationary they 
decrease BRN2 expression (92). Pinner and colleagues were the first to show in vivo evidence 
for reversible phenotype switching. Low MITF expression was seen to be inversely correlated 
with NF-kB signaling and the expression of the receptor tyrosine kinase AXL (80). NF-kB 
activation antagonized MITF expression and increased gene expression of invasion phenotype 
genes. AXL and NF-kB expression decrease the susceptibility to BRAFV600E inhibitor therapy, 
suggesting that this MITF low NF-kB high subpopulation have intrinsic resistance. Bittner et al 
(101) first demonstrated that the gene Melan-A/Melanoma Antigen Recognized by T cells-1 
(MART-1) was inversely correlated with Wnt5A expression in a large microarray study for 
nineteen melanoma samples and that WNT5a distinguished more aggressive tumors from less 
aggressive tumors. In a follow-up study, Weeraratna et al demonstrated that Wnt5A expression 
directly correlated with increasing tumor grade and that Wnt5A activated PKC signaling and led 
to increased invasion (102). Dissanayake et al showed that Wnt5A overexpression or 
knockdown using siRNA in melanoma cells identified several genes that were suppressed by 
Wnt5A overexpression, including metastasis suppressors such as Kiss-1 (97). In the same 
study they also highlighted the inverse relationship between Wnt5A and various tumor-
associated antigens of melanocytic lineage, including TYRP-1, DCT, gp100, and MART-1. 
Wnt5A can down-regulate the expression of melanoma differentiation antigens via PKC and 
STAT3 activation, suggesting that Wnt5a may contribute to immune evasion (90). Wnt5A was 
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also found to enhance resistance to BRAFV600E inhibitor therapy (103). In summary, the 
phenotype switching model describes two populations of melanoma cells with anti-correlative 
melanocytic and mesenchymal gene expression patterns, which define the proliferative and 
invasive phenotype respectively, and phenotype switching is a potential resistance mechanism 
to targeted therapy and immunotherapy. 
 
 
Figure 3. Melanoma phenotype switching model. The green spheres represent proliferative phenotype 
cells and the red spheres represent invasive phenotype cells. The model predicts that during tumor 
growth, most cells are in a proliferative state until some microenvironmental factors induce some cells to 
become invasive. These invasive cells leave the tumor bulk and establish a metastasis elsewhere by 
switching to a proliferative state. 
 
Melanoma also possesses an innate trait to respond to extracellular cues provided by the 
extracellular environment which induces a phenotype switch in an embryonic environment 
(104). The ability for melanoma cells to adapt to such an environment highlights the high degree 
of plasticity melanoma cells are capable of. Other studies have also supported the plastic nature 
of melanoma (105, 106). Many groups have isolated and injected pure homogeneous 
populations of melanoma cells into immunocompromised mice and no matter which surface 
expression markers were selected, both positive and negative populations gave rise to tumors 
and the tumors were heterogeneous for the marker (107-110). As these pure populations of 
melanoma cells have the same genetic background, these results would suggest that the 
plasticity arises from reversible epigenetic mechanisms. Indeed, epigenetic mechanisms have 
been shown to play a role in melanoma heterogeneity and tumor growth. Roesch and 
colleagues have shown that a H3K4 demethylase, JARID1B, is required for continuous tumor 
growth and importantly JARID1B regulation is dynamic as JARID1B negative cells can become 
17 
 
positive and vice versa (109). Taken together, these studies provide compelling evidence for 
epigenetic involvement in the plasticity of melanoma to give rise to phenotypic heterogeneity.  
 
DNA methylation and melanoma 
DNA methylation provides a stable gene silencing mechanism involved in regulating gene 
expression and chromatin architecture. DNA methylation is defined by the addition of a methyl 
group to the cytosine of a cytosine-phosphate-guanine (CpG) dinucleotide. A family of DNA 
methyltransferases (DNMTs) catalyzes this reaction by transferring a methyl group from the 
donor S-adenosyl methionine (SAM) to cytosine at the fifth carbon position of the pyrimidine ring 
(111-113). The maintenance methyltransferase, DNMT1, preferentially catalyzes methylation of 
the unmethylated strand of hemimethylated DNA during DNA replication (111). The de-novo 
methyltransferases, DNMT3a and DNMT3b, establish new methylation patterns on both DNA 
strands during embryogenesis or differentiation processes (reviewed in (114)). CpG 
dinucleotides are not evenly distributed throughout the genome, but they are concentrated into 
regions called CpG islands. More than half of the genes (52%) of the human genome contain a 
CpG island in their promoter region (115). DNA hypermethylation of promoter CpG islands can 
permanently silence genes, and inactivation of tumor suppressor genes by promoter 
methylation is one event that can lead to tumor progression (116, 117), whereas DNA 
hypomethylation can reactivate latent retrotransposons, induce genome stability, and activate 
proto-oncogenes which can lead to tumor progression (118, 119). Thus aberrant DNA 
methylation has two potential oncogenesis mechanisms, hypermethylation and hypomethyation.  
 
It is becoming increasingly apparent that DNA methylation plays an important role in melanoma 
development and progression (120). DNMT3a and DNMT3b are upregulated in metastatic 
melanomas compared to primary melanomas (121). Deng et al showed that DNMT3a is 
required for melanoma development and metastasis in a melanoma mouse model (122). 
Promoter hypermethylation has been detected for genes encoding factors involved in  several 
signaling pathways critical to tumor progression, genes of notable tumor suppressor function 
include adenomatous polyposis coli (APC) (123), PTEN (124), O-6-methylguanine-DNA 
methyltransferase (MGMT) (125, 126), CDKN2A (127), RASS1FA (126, 128-130), and E-
cadherin (CDH1) (126, 131). Genome-wide hypomethylation has also been observed in 
melanoma but little is known about its role in tumor initiation and progression (132). Specific 
areas of hypomethylaton have been detected at major repetitive DNA elements like LINE-1 and 
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Alu and at the melanoma antigen family A (MAGE-A) locus. However functional characterization 
of these genes has not been explored (133). Lian et al have shown that methylated cytosines 
are converted to hydroxymethylated cytosines by the ten eleven translocase (TET) family of 
dioxygenase enzymes in melanoma, and they functionally characterized this novel epigenetic 
marker and its impact on melanoma progression (134). Hydroxymethylated cytosines are the 
intermediate product of active demethylation of methylated cystosines to unmethylated cytosine 
and (135).   
 
In summary, there is convincing evidence that DNA methylation plays an important role in 
melanoma by silencing tumor suppressors and increasing genomic instability by global 
hypomethylation. 
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4. Aim of the thesis 
 
Melanoma is the most aggressive skin cancer worldwide. Although melanoma is curable when 
detected in early stages of progression, patients diagnosed with late stage and metastatic 
melanomas have very poor survival. The difficulty in treating late stage and metastatic 
melanoma patients has been attributed to the heterogeneity of melanoma. However the 
molecular mechanisms of establishing heterogeneity are currently unknown. Our laboratory 
recently described the phenotype switching model for melanoma heterogeneity.  This model 
hypothesizes that melanoma cells drive disease progression by switching between phenotypes 
of proliferation and invasion. Microarray experiments have shown that specific gene expression 
patterns differentiate between proliferative and invasive melanoma cell phenotypes. In vitro the 
proliferative and invasive phenotypes are morphologically distinct and differ in proliferation rate 
and invasiveness.  
The aims of my PhD were:  
1. Validate the phenotype switching model in other melanoma datasets 
2. Investigate specific genes involved in phenotype switching 
3. Investigate the role of DNA methylation in phenotype switching  
In Chapter 5, we published a study describing our methodology in validating the two phenotype 
gene signatures in a large set of publically accessible microarray datasets on the Gene 
Expression Omnibus (GEO) array repository. This publication demonstrated that the gene 
expression signatures for the proliferative and invasive phenotypes established with our 
melanoma cell cultures were also seen in the majority of melanoma cell cultures used in other 
melanoma research laboratories worldwide.  
In Chapter 6, we published a study describing the role of SOX9, a marker for the invasive 
phenotype, as a regulator for SOX10, a marker for the proliferative phenotype, in melanoma 
cells and in a Tyr::NrasQ61K mouse model. SOX10 haploinsufficiency was previously shown to 
prevent naevi formation and hyperpigmentation in the Tyr::NrasQ61K melanoma mouse model. In 
this publication, conditional deletion of SOX9 in both Tyr::NrasQ61K Sox10fl/- and Tyr::NrasQ61K 
Sox10fl/fl mice rescue the hyperpigmentation and naevi phenotype. In addition, SOX9 
overexpression in melanoma cell cultures leads to down-regulation of SOX10 through the 
binding of SOX9 to the SOX10 promoter. This publication demonstrated the antagonistic roles 
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of SOX10 and SOX9 expression in melanoma development and potentially supports the 
phenotype switching model.  
In Chapter 7, we published a study describing the landscape of DNA methylation between the 
proliferative and invasive phenotype, and functionally validated SOX9 as a marker for the 
invasive phenotype and correlate its expression and function with patient survival. SOX9 in 
chapter 6 was shown to suppress the proliferative phenotype by downregulation of SOX10. In 
this publication, DNA methylation regulates the expression of SOX9 and SOX9 is required for 
the invasive capacity of melanoma cells. Furthermore, high SOX9 expression was correlated 
with poor patient survival. This publication demonstrated the prognostic role of SOX9 in 
melanoma and the characterization of SOX9 in the invasive phenotype.  
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 5. Systematic classification of melanoma cells by phenotype-specific 
gene expression mapping 
 
Contribution 
In this publication, I helped curate the datasets from the GEO database and perform some 
preliminary analysis on the proliferative and invasive gene signatures in the external datasets. I 
also performed the proliferation and invasion characterization experiments for a number of cell 
cultures. I was made second author for my contributions to this paper. 
This study was published in Pigment Cell Melanoma Research; Widmer et al. 2012.  
Summary 
There is growing evidence that the metastatic spread of melanoma is driven not by a linear 
increase in tumorigenic aggressiveness, but rather by switching back-and-forth between two 
different phenotypes of metastatic potential. In vitro these phenotypes are respectively defined 
by the characteristics of strong proliferation/weak invasiveness and weak proliferation/strong 
invasiveness. Melanoma cell phenotype is tightly linked to gene expression.  Taking 
advantage of this we have developed a gene expression-based tool for predicting phenotype 
called Heuristic Online Phenotype Prediction (HOPP). We demonstrate the predictive utility of 
this tool by comparing phenotype-specific signatures with measurements of characteristics of 
melanoma phenotype-specific biology in different melanoma cell lines and short-term cultures. 
We further show that 86% of 536 tested melanoma lines and short-term cultures are 
significantly associated with the phenotypes we describe. These findings reinforce the 
concept that a two-state system, as described by the phenotype switching model, underlies 
melanoma progression. 
 
Significance 
 
A recent model for melanoma progression suggests that melanoma cells switch back-and- 
forth  between  states  of  proliferation  and  invasion  to  drive  disease  progression.  We 
describe the use of a new online expression-analysis tool which shows that melanoma cell 
expression   signatures   are divided   into distinct groups   correlating   with behavioural 
phenotypes of proliferation or invasion. Using this tool we also show evidence suggesting 
that short term cultures, rather than cell lines, may be a more relevant model system for in 
vitro studies of melanoma. 
Introduction 
 
Cutaneous melanoma is an aggressively dangerous disease and median patient survival 
after metastases are diagnosed is only 6-9 months (Klimek et al., 2000). While recent 
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clinical trials have shown some improvements in overall survival for patients undergoing 
nonspecific  immune  or kinase  inhibitor  therapies,  median  survival  rates  remain  dismal 
(Hodi et al., 2010, Flaherty et al., 2010, Chapman et al., 2011). Therefore gaining a 
comprehensive cellular and molecular understanding of metastatic spread continues to be 
critically important. A major focus of study is the phenomenon of melanoma cell heterogeneity.  
That there can be significant molecular differences between  melanoma cells from the same 
lesion is widely appreciated, though what this means for disease progression remains the 
subject of debate (Shackleton and Quintana, 2010, Hoek and Goding, 2010, Roesch et al., 
2010). 
Pursuing in vitro studies into melanoma heterogeneity, we and others have identified two 
subgroups  of  cultured  melanoma  cells  which  are  clearly  distinguishable  by  how  they 
express specific genes (Bittner et al., 2000, Hoek et al., 2006, Jeffs et al., 2009, Alexaki et al., 
2010, Javelaud et al., 2011). In vitro experiments have identified one subgroup as a 
proliferative   phenotype   and  the  other  as  an  invasive  phenotype,  and 
immunohistochemical testing has shown that individual primary and metastatic lesions typically  
include  cells of both phenotypes  (Eichhoff  et al., 2010, Eichhoff  et al., 2011). Their co-
presence in lesions is likely explained by experiments which have shown that melanoma  cells 
can switch between phenotypes  in vivo (Hoek et al., 2008a). Together these findings 
prompted what has become the phenotype switching model for melanoma progression, in 
which melanoma cells respond to changing microenvironmental  signals by reprogramming   
their  gene  expression  to  switch  between  states  of  proliferation  and invasion (Hoek et 
al., 2008a, Pinner et al., 2009, Hoek and Goding, 2010). In addition to providing a 
mechanism for the metastatic cascade and explaining heterogeneity  within a lesion,  
phenotype  switching  may  also  underlie  targeted  therapy  escape.  For example, slow-
cycling invasive phenotype melanoma cells would be less susceptible to standard 
chemotherapies  and such survivors could later switch to a proliferative state (Fukunaga- 
Kalabis et al., 2011). Furthermore,  cultures of invasive and proliferative  phenotype  cells 
have   been   shown   to   differentially   express   melanocytic   markers,   suggesting   that 
subverting the immune response to specifically target melanocytic  cells may be similarly 
defeated  (Hoek et al., 2006). Finally, we have shown that while proliferative  phenotype 
cells respond to MAPK inhibitors, invasive phenotype cells do not and may provide a pool 
from which resistant cells emerge (Zipser et al., 2011). 
Most recently, our group showed that microenvironmentally-induced changes in the 
expression patterns of specific LEF/TCF family transcription factors may be important for the 
phenotype switching mechanism (Eichhoff et al., 2011). That the microenvironment  is 
involved in phenotype switching is corroborated by the results of other groups who have 
explored its influence on melanoma gene expression  and metastatic  potential (Seftor et al., 
2006, Folberg et al., 2006, Postovit et al., 2008). Several laboratories have considered the  
phenotype  switching  model  and  reported  data  supporting  a  relationship  between factors 
expressed  in a phenotype-specific  manner and disease progression  (Carreira  et al., 2006, 
Almanzar et al., 2009, Orgaz et al., 2009, O'Connell et al., 2009, Alexaki et al.,2010). These 
studies contrast those which purport to identify melanoma stem cells (or melanoma initiating 
cells) by the identification of stem-cell markers (Fang et al., 2005, Schatton et al., 2008). While 
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the melanoma stem cell paradigm also seeks to explain intralesional  heterogeneity  and  
therapy  escape,  several  lines  of research  indicate  that stem cell markers are not an 
exclusive or even necessary prerogative of cells propagating metastatic disease (Quintana et 
al., 2008, Roesch et al., 2010, Cheli et al., 2011). The inference  is  that  “stemness”  is  a  
reversible  phenotype  to  be  adopted  or  shed  by melanoma cells in response to 
microenvironmental  signalling (Hoek and Goding, 2010). The  reversible  nature  of  stem  
cell  marker  expression  closely  mirrors  the  concept  of phenotype switching, and we have 
argued that invasive phenotype melanoma cells themselves fit multiple criteria for cancer 
stem cells (Hoek and Goding, 2010). Thus it is critical that researchers working with 
melanoma cells are both aware of and can account for the phenotypes as they study various 
aspects of melanoma biology. 
We  have  designed  a  gene  expression   analysis  algorithm,  termed  Heuristic   Online 
Phenotype   Prediction   (HOPP),  which  uses  archetypes   of  proliferative   and  invasive 
phenotype signatures to identify and predict the phenotypes  of melanoma cell lines and 
cultures.  We tested  its utility by carrying  out proliferation  and invasion  experiments  on 
both short-term melanoma cultures and widely-used melanoma cell lines. We also used HOPP 
to carry out a phenotyping survey of several hundred published expression profiling 
experiments  which  showed  that,  contrary  to  the  expectation   that  samples  may  be 
uniformly distributed throughout the “expression  space” between phenotypes, more than 
80% of samples cluster with either the proliferative or the invasive phenotype. 
 
Results 
 
 
Melanoma phenotype specific gene expression 
For high throughput studies of melanoma gene expression, the most frequently employed 
platform  remains  the  HG-U133  series  produced  by  Affymetrix  (Hoek,  2007).  In  our 
experience  this  platform  has  proven  to  be  a  robust  tool  for  genome-wide  expression 
studies  (Hoek  et  al.,  2006,  Zipser  et  al.,  2011).  Therefore  the  current  study  sources 
datasets  produced  using  HG-U133  series  platforms.  We  used  six  different  datasets 
(including a total of 218 melanoma lines and cultures) to derive the phenotype signature 
standards. For each dataset we performed a class-discovery  analysis following methods 
previously described (Hoek et al., 2006), with the modification that we used bootstrapped 
confidence estimates for determining phenotype membership based on sample clustering 
(Kerr and Churchill, 2001). From this we identified 100 samples in one subgroup and 92 
samples in a second subgroup (Appendix; Table S1). A further 26 samples did not show 
100% stability in their cluster memberships and were therefore not used to identify genes 
with  subgroup-specific  expression  patterns.  With  the  subgroup  assignments  we  used 
ANOVA to identify a set of 97 genes expressed differentially between the two subgroups 
(Appendix;  Table  S2).  Reference  to  earlier  works  with  similar  expression  signatures 
derived from smaller datasets indicated that the first subgroup are characterized by a 
proliferative phenotype signature and the other by an invasive phenotype signature (Hoek et 
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al., 2006,  Jeffs  et al., 2009).  The  identified  list of genes  is thus  referred  to as the 
Melanoma Phenotype-Specific Expression (MPSE) list. 
 
 
Generating MPSE correlation data 
Normalization  of  high  throughput  data  across  samples  within  a  dataset  is  principally 
designed to account for dataset-specific  sources of technical variation. However, different 
datasets   do  not  necessarily   share  equivalent   characteristics   of  variation   and  it  is 
impractical  to expect  that analyses  of combined  datasets  would  not be susceptible  to 
these differences. Our aim was to devise a method for predicting phenotype from gene 
expression data for single-sample experiments (where cross-sample normalization procedures  
do  not  apply)  as  well  as  for  multi-sample  experiments  (considering  each sample 
independently). We extracted the raw signal intensities for 134 probe-sets corresponding to 
the 97 MPSE genes from 192 samples (the control set) representing 100 proliferative  and  
92  invasive  phenotype  signatures  (Table  S1).  For  each phenotype we then calculated 
the median cross-sample values for every probe-set. This yielded two phenotype-specific 
standard signatures (Table S2). An online algorithm, Heuristic Online Phenotype Prediction 
(HOPP, http://www.jurmo.ch/hopp), was written to perform Pearson’s correlation analyses 
comparing data from each phenotype- assigned sample against both the invasive and the 
proliferative standards, yielding two correlation   coefficients   per  sample.   We  graph  the  
function   of  the  two  correlation coefficients   on  a  simple   cartesian   coordinate   system   
where   the  x-axis   describes correlation with the proliferative phenotype signature standard, 
and the y-axis describes correlation with the invasive phenotype signature standard, referring 
to this particular arrangement as a “Widmer plot”. 
Plotting of sample correlation coefficients showed group-specific clustering of proliferative 
and the invasive phenotype samples (Figure 1A; Table S3). We used this data to  calculate   
the  probability   density   distribution,   which   also   showed   group-specific clustering  of the  
samples  and  indicated  a strong  peak  near  the  proliferative  standard (Figure 1B). We 
acquired DNA microarray data for an additional 318 in vitro melanoma gene expression 
profiling experiments from the NCBI GEO database (http://www.ncbi.nlm.nih.gov/geo/) and 
used HOPP to also calculate and plot their sample correlation coefficients. This revealed a 
distribution closely similar to that of the control set (Figure  1C; Table S4). Calculating  the 
probability  density distribution  reveals similar results as obtained with the control set (Figure 
1D). Including the highly stringent Bonferroni  multiple  testing  correction  adjustment,  we  
calculate  the  significance  of  a Pearson's correlation (r) of 0.4 to be P < 0.001. This shows 
that 81% of samples have expression signatures which are closely correlated (r > 0.4) to only 
one standard. In comparison, 1% of samples were closely correlated to both and 18% were 
not correlated to either. It should be appreciated that, because of the high number of samples 
being examined (the panels in Figure 1 describe the results obtained from a total of 536 
profiling experiments) there is a high likelihood that some of these apparent outliers are the 
result of technical fault. For example, common faults that may be expected to affect the 
outcome on a Widmer plot include the use of degraded RNA samples to perform gene 
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profiling experiments, or using samples which are contaminated with additional cells from other 
sources. 
 
 
 
 
 
FIGURE 1. MPSE correlation plots. Sample gene expression data for the MPSE gene set was used 
to calculate, via HOPP, correlation coefficients (r values) against the proliferative and invasive standard 
signatures. (A) Widmer plot (proliferative (x-axis) versus invasive (y-axis) correlation coefficients) of the 
control data. This shows that 93.2% of samples yielded r > 0.4 for one phenotype only, 4.5% yielded r > 
0.4 for both phenotypes and 2.3% yielded r > 0.4 for neither. (B) The kernel density estimation of the 
probability distribution for control data shows distinct sample concentrations near each phenotype 
standard. (C) Widmer plot of 318 test samples. This shows that 81.4% of samples yielded r > 0.4 for one 
phenotype only, 1.2% yielded r > 0.4 for both phenotypes and 17.4% yielded r > 0.4 for neither. (D) The 
kernel density estimation of the probability distribution for the test samples also shows distinct sample 
concentrations near the phenotype standards. 
 
 
 
 
Assessing phenotype prediction for melanoma cultures and cell lines 
 
We performed DNA microarray gene expression profiling on twelve additional short-term 
melanoma cell cultures and used HOPP to predict their phenotypes (Figure 2A). We then 
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tested their in vitro characteristics  of proliferation  and invasion. Under standard culturing 
conditions the six proliferative signature samples had an average population doubling time of 
42.9 h, while the six invasive signature samples had an average population  doubling time 
of 131.3 h (Figure 2C). In invasion assays the proliferative signature samples showed an 
average invasive index of 3.2%, while the invasive signature samples had an average 
invasive index of 30.3% (Figure 2E). These differences in proliferation and invasion were 
significant (P < 0.002 and P < 0.004, respectively). Culturing of these cells on Matrigel, as 
described previously (Zipser et al., 2011), yields surface organization patterns which are 
phenotype specific. Proliferative phenotype melanoma cells adopt an organization of small 
and isolated clusters, while invasive phenotype cells form connected networks (Appendix; 
Figure S1). Culturing short-term melanoma cell cultures on Matrigel confirmed phenotype- 
specific surface organization patterns (Table 1). 
 
Table 1. Combined summary data for melanoma cell cultures. 
 
 
Cell cultures 
 
Accession 
 
Correlation 
Pro (r) 
 
Correlation 
Inv (r) 
 
Doubling 
time (h) 
 
Invasion 
(%) 
Matrigela 
M080423 GSM700746 0.831 -0.122 70.9 5.3 isolated 
M000921 GSM700745 0.550 0.050 42.4 7.8 isolated 
M010817 GSM700743 0.734 -0.046 42.9 0.9 isolated 
M980513 GSM700742 0.891 -0.074 37.1 0.0 isolated 
M050829 GSM700744 0.618 0.215 33.3 3.0 isolated 
M000907 GSM108375 0.511 0.260 30.5 2.4 isolated 
M060125 GSM700750 -0.121 0.806 184.0 30.4 connected 
M061103 GSM700749 -0.131 0.769 164.9 42.1 connected 
M081008 GSM700752 -0.147 0.718 73.6 11.8 connected 
M080310 GSM833481 -0.154 0.773 159.8 13.6 connected 
M080201 GSM833482 -0.187 0.685 145.9 20.8 connected 
M080214 GSM833483 -0.178 0.774 59.3 63.4 connected 
 
a see Figure S1 for explanatory examples. 
 
Table 2. Combined summary data for melanoma cell lines 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cell line Accession Correlation 
Pro (r) 
Correlation 
Inv (r) 
Doubling 
time (h) 
Invasion 
(%) 
Matrigela 
888mel GSM206439 0.802 -0.052 27.8 8.8 isolated 
WM983A GSM109047 0.878 -0.027 46.7 2.8 isolated 
WM983B GSM109048 0.860 -0.052 49.0 0.9 isolated 
501mel GSM555120 0.831 -0.012 22.8 7.8 connected 
SK-MEL-28 GSM206543 0.947 -0.082 24.5 1.6 connected 
WM793B GSM109043 -0.119 0.939 39.0 20.0 connected 
WM852 GSM109044 -0.134 0.804 41.0 15.9 connected 
1205Lu GSM109021 -0.088 0.924 24.2 5.4 connected 
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a  see Figure S1 for explanatory examples. 
 
We compared the short-term culture results with a similar analysis of eight widely-used 
melanoma lines (SK-MEL-28, 501mel, 888mel, WM793, WM852, WM983A, WM983B and 
1205Lu).  Each of these has already been subject to microarray  expression  profiling  by 
other researchers and this data is available on the NCBI GEO database. However, we 
performed additional DNA microarray expression profiling experiments on these lines and 
used  HOPP  to  predict  their  phenotypes  (Figure  2B).  This  showed  close  agreement 
between the published  data and our experiments,  where five are proliferative  signature 
lines (888mel, WM983A, WM983B, 501mel, SK-MEL-28) and three are invasive signature 
lines  (WM793B,  WM852,  1205Lu).  Then  we  assessed  their  in  vitro  proliferative  and 
invasive characteristics.  We found for these cell lines that while there was no significant 
difference in population doubling times between proliferative (34.1 h) and invasive (34.7 h) 
signature lines (Figure 2D), there was a significant difference (P < 0.026) in invasiveness, 
with proliferative signature lines showing an invasive index of 4.4% and invasive signature 
lines showing an invasive index of 13.8% (Figure 2F) in line with previous observations 
(Alexaki  et al., 2010).  However,  culturing  of cell lines  on Matrigel  yielded  inconsistent 
results, with two (501mel, SK-MEL-28) yielding outcomes which were contra to HOPP 
prediction (Table 2, Figure S1). 
 
 
 
 
FIGURE 2. Phenotype prediction of in vitro behaviours. (A) Widmer plot of HOPP data from short- term 
cultures of melanoma cells. (B) Widmer plot of HOPP data from melanoma cell lines. (C) In vitro doubling 
time (h) of short-term cultures of melanoma cells. (D) In vitro doubling time (h) of melanoma cell lines. (E) 
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In vitro invasive indices of short-term cultures of melanoma cells. (F) In vitro invasive indices of melanoma 
cell lines (*P < 0.05, **P <0.01). Dotted lines in the Widmer plots indicate r = 0.4. 
 
 
 
 
Phenotype is independent of BRAF mutation status 
The BRAFV600E   mutation  is a frequent  occurrence  in melanoma,  being present in more 
than half of all samples tested (Davies et al., 2002). The involvement of this mutation in 
disease progression  has shown BRAF to be a promising  target molecule  in therapeutic 
trials (Flaherty et al., 2010, Bollag et al., 2010). We therefore explored whether the BRAF 
mutation  had any relationship  with the proliferative  and invasive  phenotype  signatures. 
Four different  datasets  (GSE10916,  GSE4841,  GSE4843  and GSE7127)  supply 
genotyping information concerning the mutation status of BRAF. HOPP analyses of these 
show there is no significant  association  between  the HOPP result and BRAF mutation 
status  (Figure  3).  This  indicates  that  BRAF  mutation  status  has  no  relationship  with 
phenotype-specific gene expression. 
 
 
 
 
 
 
 
 
FIGURE 3. Phenotype and BRAF mutation. Datasets for which BRAF mutation status data was 
available  were  subjected  to  HOPP  analysis  and  the  distributions  of  BRAF  wild-type  versus 
BRAFV600E were assessed. Widmer plots of four different datasets reveals no significant relationship 
between BRAF mutation status and HOPP outcome. Dotted lines indicate r = 0.4. 
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Melanoma cell phenotypes in vivo 
In  vitro,  melanoma  cell phenotype  is  assumed  to  be  relatively  homogenous  and  it  is 
supposed that nearly all cells in a given culture share a uniform level of gene expression. In 
contrast to this, in vivo observation of melanoma tumors reveal a heterogeneous distribution   
of  many  markers   as  tumors   typically   include   an  irregularly   distributed composition  of 
tumor,  stromal  and  infiltrating  immune  cells.  The  distribution  of marker genes  specific  to  
invasive  or  proliferative  phenotypes  suggest  that  tumors,  and  the biopsies taken from 
them, also include cells of both phenotypes in proportions which are difficult to predict. 
Subsequently,  while the measurement  of the expression of any given gene is its mean 
among all cells in a biopsy, it does not necessarily follow that this is representative of the 
entire lesion. Thus tumor heterogeneity, with its irregular distribution of cell phenotypes, likely 
complicates the drawing of clinically relevant conclusions from expression  data  obtained  
from  either  biopsies  or  derived  cell  cultures.  We  therefore examined  data  obtained  from  
melanoma  tissue  samples  and  used  HOPP  to  perform Pearson   correlation   analyses   
against  the  proliferative   and  invasive   standards.   For example, Riker and co-workers 
published a study in which, among other things, they compared primary melanomas  against 
metastatic  lesions (Riker et al., 2008). We found that HOPP analysis does not separate 
these sample classes, with both primaries and metastases  being similarly  spread  between  
proliferative  and invasive  phenotype signatures  (Figure  4A).  This  supports  earlier  data  
which  indicated  that  primary  and metastatic lesions are composed of irregular distributions 
of both phenotypes (Hoek et al.,2006, Eichhoff et al., 2011). 
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FIGURE 4. Primary versus metastatic melanoma tissues and cultures. (A) The Riker dataset (GSE7553) 
was assessed with HOPP and is shown here as a Widmer plot with samples identified according to 
whether they are primary melanoma tissue (crosses) or metastatic melanoma tissue (squares). (B) The 
Philadelphia dataset (GSE4841) was assessed with HOPP and the results are displayed here as a 
Widmer plot with samples identified according to whether they are primary melanoma cells (crosses) or 
metastatic melanoma cells (squares). Neither primary nor metastatic melanoma samples reveal a 
significant association with the phenotype signatures. Dotted lines indicate r = 0.4. 
 
 
 
 
Comparison with hierarchical clustering 
 
Freedman and co-workers profiled gene expression in cultures of primary and metastatic 
melanoma lesions and categorized them according to unsupervised hierarchical clustering 
(Freedman et al., 2011). Re-analysis of this data using HOPP shows that their M1 and M3 
subclasses   fit  discretely   into   the   proliferative   and   invasive   phenotype   signatures, 
respectively (Figure 5). 
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FIGURE 5. Hierarchical clustering versus HOPP. The Freedman data was assessed with HOPP and the 
results are displayed here as a Widmer plot with cultured samples identified according to the M1 
(crosses) and M3 (squares) clustering results obtained by Freedman and co-workers. Dotted lines 
indicate r = 0.4. 
 
 
 
 
Interlaboratory phenotype signature consistency 
 
We compared HOPP analyses for nine different cell lines where for which were at least 
three  independent  sources  of  expression  profiling  data.  Widmer  plots  of  the  results 
showed that four cell lines (WM35, MDA435, A2058 and A375) demonstrated inconsistent 
phenotype  signatures.  In contrast,  five cell lines (SK-MEL-28,  C8161, MALME-3M,  SK- 
MEL-19 and SK-MEL-5) showed consistent phenotype signatures (Figure 6). 
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FIGURE 6. Melanoma cell line expression signature inconsistencies. The results of HOPP analyses of 
data taken from four different cell lines in wide use, each of which was expression profiled by at least 
three different laboratories, are shown here as Widmer plots. These data show that melanoma lines 
WM35, MDA435 and A2058 show little inter-laboratory consistency in their gene signatures. On the 
other hand, seven different laboratories yielded SK-Mel-28 expression data which showed a strongly 
consistent proliferative phenotype signature. Dotted lines indicate r=0.4. 
Discussion 
 
Previous studies which identified two phenotypes of melanoma cell yielded some clues 
concerning the molecular nature of phenotype switching (Hoek et al., 2006, Carreira et 
al.,2006). However, it was not clear if there were distinct intermediate stages between the 
proliferative  and  invasive  archetypes.  We  show  here  that  a  large  majority  of  gene 
expression profiles derived from melanoma in vitro cluster very closely to one or the other 
phenotype standard. This argues against the idea that melanoma cells adopt clear intermediate 
states during phenotype switching and counters an earlier suggestion that melanoma cells may 
inhabit a “continuum” in the expression space between phenotype standards (Hoek et al., 
2008a). 
We tested the ability of HOPP to predict in vitro behaviours in a dozen short-term cultures of 
melanoma cells and eight widely-used melanoma cell lines (Figure 2). We found close 
correlation  between HOPP clustering  and the in vitro proliferative  and invasive 
characteristics  of short-term  cultures. This showed a close association  between specific 
gene  expression  patterns  and  in  vitro  biological  activities  of  short-term   cultures  of 
melanoma cells, meaning that HOPP may be used with confidence to predict their 
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characteristics. Similarly, our in vitro characterization of cell lines showed that in vitro 
invasiveness correlated closely with phenotype specific expression patterns. However, we 
found  no  such  significant   signature-specific   difference   between   cell  lines’  rates  of 
proliferation. Overall, cell lines of both phenotypes proliferated significantly faster than invasive 
phenotype cell cultures, and were at least as fast as proliferative phenotype cell cultures.  
Why cell lines proliferate  so well may be explained  by the effects  of somatic changes and 
experimenter selection. Cells in culture likely remain subject to additional somatic changes 
which could contribute  towards the selection  of faster growing clones. For example, such 
changes may influence proliferation-critical processes such as cyclin degradation, where it has 
been shown that truncation of cyclin genes abrogates normal processes   nuclear   expulsion   
and  cytosolic   degradation   (Van  Dross   et  al.,  2006). Furthermore, cells which did not 
proliferate well in culture were routinely discarded on the basis  that  they  were  probably  not  
cancer  cells.  This  is  understandable  with  a  clonal evolution model in which cancer cells 
are thought to increase characteristics of both proliferation  and  invasion  as  the  disease  
progresses  (Miller  and  Mihm,  2006).  The differences between short-term cultures and cell 
lines, in which the phenotypic behaviours of cell lines are less correlated with their expression 
signatures, suggest that over the long period of time cell lines have been in circulation they 
may have deviated from their original characteristics  and been  selected  for by researchers’  
expectations  of what constituted good in vitro models. 
Many melanoma researchers use cell lines or cultures to study the disease. As mentioned 
earlier, a fundamentally important assumption had been that melanoma cells may be 
differentiated  by their  potential  to drive  metastatic  progression.  The  language  used  to 
convey  the  extent  or degree  of this  potential  in  a given  cell  line  or culture  is  varied. 
Descriptors are sometimes determined by the clinical stage of the lesions from which cells are 
derived. This can influence conclusions drawn on the basis that differences between lines 
are significantly correlated with interpretations in which clinical stage reflects aggressiveness. 
For example, Pochec and co-workers use the fact that A375 comes from a metastasis and 
WM35 comes from a primary to make the claim that differences in how these cells 
glycosylate an integrin is significant for the acquisition of invasiveness (Pochec et  al.,  2003).  
Similarly,  the  Wistar  Institute  Melanoma  Research  Center  maintains  a collection  of 
melanoma  cell lines which are explicitly characterized  according  to clinical stages  of the 
patient  lesions  from  which  they are derived (http://www.wistar.org/lab/meenhard-herlyn-
dvm-dsc/page/resources). However, our previously published analyses (Hoek et al., 2006) 
found no gene expression pattern correlating with stage progression in these lines and HOPP 
analysis confirms that their distribution is not phenotype specific. Alternatively, descriptors 
may be derived experimentally, for example cells may be described as “metastatic” or “non-
metastatic” according to their performance in animal models (de Wit et al., 2005). In either 
context, differences  between  “metastatic”  and “non-metastatic”  are  frequently  interpreted  
in the same way as being intrinsic to disease progression. However, this is problematic 
because a  cell  line  derived  from  a metastasis  may  not  necessarily  produce  metastases  
in  an animal model. 
A significant consequence of a paradigm in which the existence of two distinct phenotypes of 
melanoma  cell goes unrecognized  is the likelihood  of large-scale  study bias towards one 
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or another phenotype. For example, scientists studying DNA methylation patterns in 
melanoma  examined  eleven different  cell cultures  (Bonazzi  et al., 2011). Of these, we 
note (from Table S1) that nine have clear proliferative phenotype signatures and one has a 
clear  invasive  phenotype  signature.  It is probable  that the  reason  for this  is simply 
because proliferative  phenotype  signature  melanoma  cultures  grow faster and are thus 
more amenable to in vitro research than slower-growing invasive phenotype cultures. The 
results  of  these  researchers’   experiments   are  therefore   biased  toward  proliferative 
phenotype  cells. Considering  our probability  density  calculations  it is clear that a large 
majority  of  experiments   have  been  conducted   on  proliferative   phenotype   cultures, 
suggesting that this bias is wide-spread. 
Interestingly, other workers have performed expression profiling analyses and clustering 
experiments which yielded distributions of data strikingly similar to the partition described by 
phenotype switching. For example, Freedman and co-workers profiled gene expression in 
cultures of primary and metastatic melanoma lesions and categorized them according to 
unsupervised hierarchical clustering (Freedman et al., 2011). Our analysis of this data 
showed that their M1 and M3 subclasses fit into the proliferative and invasive phenotype 
signatures,  respectively.  By  gene  enrichment  analyses  and  pathway  activity  analyses 
these  researchers  identified  distinct  patterns  of  pathway  activation.  The  M1  subclass 
exhibited  stronger  activity  of  the  β -catenin,  EGFR  and  ER  pathways  while  the  M3 
subclass showed higher activity of SRC and STAT3 pathways. STAT3 signalling is known to 
induce  expression  of MMP2  and VEGF,  genes  which  are highly  upregulated  in the 
invasive phenotype (Niu et al., 2002, Wei et al., 2003, Xie et al., 2004). Interestingly, due to 
the activation of STAT3 in the M3 subclass and the reported importance of STAT3 activation 
for the formation of metastases in a mouse model (Xie et al., 2004), Freedman and co-
workers suggested that the M3 subclass is a more aggressive subset. This is important 
because it relates to how the meaning of a term like “aggressive” is contextually nuanced.  
For  example,  it  is  implied  that  the  M1  subset,  which  shows  higher  EGFR pathway 
activity, is less aggressive. This interpretation contrasts with other studies which report that 
EGFR pathway activation is critical for promoting tumor growth and metastasis, and which  
conclude  that EGFR  pathway  activation  is characteristic  of aggressive  cells (Ueno et al., 
2008, Schartl et al., 2010). Our own interpretation is that these results are not in conflict 
because they are likely dealing with different phenotypic states. In this context, STAT3 
signalling is important for driving invasiveness, while EGFR signalling is critical for 
proliferation. As both phenotypes are required for metastatic spread it is understandable 
that suppression  of either pathway  would retard the aspects  of disease  progression  to 
which they respectively apply. 
In a previous study we examined the effects of MAP kinase inhibition on proliferative and 
invasive phenotype melanoma cells (Zipser et al., 2011). While this showed that response to  
MAP   kinase   inhibition   was  phenotype-specific,   we  also   saw  evidence   for  the 
involvement  of MAP kinase activity in phenotype  regulation.  Specifically,  we noted that 
MAP kinase inhibition of proliferative phenotype cells induced the acquisition of invasive 
phenotype characteristics, which would revert upon removal of the inhibitor. Though 
expression  profiling  was  performed  on  these  samples,  we  found  that  MAP  kinase 
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inhibition  induced  no  significant  change  in  gene  expression  and  analysis  by  HOPP 
confirmed this (data not shown). The transience of the induced changes seen suggests 
how melanoma cells in vitro maintain their phenotype. Under standard culturing conditions 
neither proliferative phenotype cells nor invasive phenotype cells have been observed to 
undergo  phenotype  change  (Hoek  et  al.,  2006).  This  may  seem  inconsistent  with  a 
phenotype  switching  model  which  holds  that  microenvironmental   influence  is  key  to 
phenotype change (Hoek et al., 2008a). However, we suggest that the particular 
microenvironmental  influences required for phenotype change are absent under standard 
culturing conditions, allowing different phenotypes to persist (Eichhoff et al., 2011). 
Scientists  have been culturing cancer cells (including melanoma)  from patient materials for 
a century (Losee and Ebeling, 1914) and immortalized cancer cell lines have been available 
for sixty years (Gey et al., 1952). Accordingly, there are many human melanoma cell lines 
which  have been in common  use for decades.  For example,  SK-Mel-28  and A375 are 
widely recognized examples of “standard” melanoma lines that have been in circulation  since  
the 1970s.  While  it is a general  assumption  that any given  aliquot  is representative of a 
cell line, passage through the years (and many hands) can lead to confusion.  Accordingly,  
we  have  found  that  distinct  batches  of  a  cell  line  can  yield inconsistent results when 
examined using the HOPP algorithm. It is important that these results show that many cell 
lines are consistent in their phenotype  signature, and while this doesn’t prove the identity of 
a cell line, it is circumstantial evidence to that effect and at the very least indicates that it the 
phenotype it is supposed to be. For cell lines where there is little agreement in HOPP 
results (e.g. A375) one is left to wonder which are the exemplars and which have become 
compromised. 
Finally,  the principles  of HOPP  can be readily  applied  to any system  where  a pair of 
standard  signatures  may  be  used  in  the  analysis  of  single  samples.  So  long  as  the 
standards were generated with sufficient samples to establish signatures with statistical 
confidence,  then subsequent  samples may be measured  against such standards in the 
same way as we have described here for melanoma cells. While the MPSE standards for 
proliferative and invasive melanoma cell phenotypes are the default for HOPP, users may 
upload their own standards instead. 
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6. Antagonistic cross-regulation between Sox9 and Sox10 controls an 
anti-tumorigenic program in melanoma 
 
Contribution 
In this publication, I performed all the in vitro experiments involving characterization of SOX10 
and SOX9 in melanocytes, naevi cells, and melanoma cells, knockdown of SOX10 and SOX9 in 
melanoma cells, and the generation of SOX9 overexpressing melanoma cells. I also analyzed 
the gene expression microarray data for the SOX9 overexpressing melanoma cells. I was made 
second author for my contributions to this paper. 
This study was published in PLoS Genetics; Shakhova et al. 2015.  
Abstract 
Melanoma is the most fatal skin cancer, but the etiology of this devastating disease is still 
poorly understood. Recently, the transcription factor Sox10 has been shown to promote both 
melanoma initiation and progression. Reducing SOX10 expression levels in human melanoma 
cells and in a genetic melanoma mouse model, efficiently abolishes tumorigenesis by inducing 
cell cycle exit and apoptosis. Here, we show that this anti--‐tumorigenic effect functionally 
involves SOX9, a factor related to SOX10 and upregulated in melanoma cells upon loss of 
SOX10. Unlike SOX10, SOX9 is not required for normal melanocyte stem cell function, the 
formation of hyperplastic lesions, and melanoma initiation. To the contrary, SOX9 
overexpression results in cell cycle arrest, apoptosis, and a gene expression profile shared by 
melanoma cells with reduced SOX10 expression. Moreover, SOX9 binds to the SOX10 
promoter and induces downregulation of SOX10 expression, revealing a feedback loop 
reinforcing the SOX10 low/SOX9 high anti--‐tumorigenic program. Finally, SOX9 is required in 
vitro and in vivo for the anti--‐tumorigenic effect achieved by reducing SOX10 expression. Thus, 
SOX10 and SOX9 are functionally antagonistic regulators of melanoma development. 
 
Author Summary 
For the development of future cancer therapies it is imperative to understand the molecular 
processes underlying tumor initiation and expansion. Many key factors involved in these 
processes have been identified based on cell culture and transplantation experiments,  but  
their  relevance  for  tumor  formation  and disease progression in the living organism is often 
unclear. Therefore, genetically modified mice spontaneously developing tumors present 
indispensable models for cancer research. Here, we address this issue by studying the 
formation of melanoma, the most fatal skin tumor in industrialized countries. To this end, we 
use a transgenic mouse model to elucidate cellular and molecular mechanisms regulating 
congenital nevus and melanoma initiation. We show that a transcription factor called SOX10 
promotes melanoma formation by repressing an anti--‐tumorigenic  program involving the  
activity of  a  related factor, SOX9. When SOX10 is inactivated, SOX9 becomes upregulated 
and induces cell cycle arrest and death in melanoma cells. Furthermore, upon experimental 
elevation of SOX9 levels, SOX10 activity is suppressed, revealing an antagonistic relationship 
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between SOX9 and SOX10 in melanoma initiation. Knowledge of how an anti--‐tumorigenic 
program can be stimulated by modulating the activities of these key factors might help to design 
novel therapeutic strategies. 
 
Introduction 
Sox (Sry (sex determining region Y)--‐related HMG box) genes encode a family of transcription 
factors that are characterized by a conserved high--‐mobility group (HMG) domain mediating 
their binding to DNA in a sequence--‐specific manner [1--‐3]. While the majority of Sox proteins 
functions as transcriptional activators, some members of the Sox family including Sox9 and 
Sox10 may also act as transcriptional repressors [4--‐6]. Sox genes play key roles in embryonic 
development and are major determinants of stem cell behavior, regulating cell fate decisions 
and maintaining cellular identity [3]. Their crucial role in normal tissue formation and 
homeostasis is evident from the fact that several mutations in  Sox  genes  are  causative  for  
developmental  diseases,  and  accumulating evidence demonstrates the important functional 
role of Sox family proteins in a variety of cancers [7--‐10]. 
A common feature of SoxE group proteins, which includes Sox9 and Sox10, is their 
expression in neural crest (NC) cells during embryonic development [2,11]. NC cells are a 
transient embryonic cell population that gives rise to most of the peripheral nervous system, 
chondrocytes and osteoblasts of craniofacial structures, smooth muscle cells of the 
cardiovascular system, and melanocytes, the pigmented cells of the skin [12]. While Sox9 is 
expressed in premigratory NC cells and in the pharyngeal apparatus, Sox10 is found in NC 
cells at the time of their emigration and is essential for their self--‐renewal and survival [12--‐16]. 
Loss of Sox10 results in absence of most NC derivatives, whereas Sox10 haploinsufficiency 
causes Waardenburg Hirschsprung syndrome, characterized by aganglionic megacolon, 
pigmentary abnormalities and often deafness due to loss of sensory innervation [13, 17--‐20]. In 
the melanocytic lineage, Sox10 is expressed during all stages of development as well as in the 
adult and is required in different species for the generation and homeostasis of embryonic and 
adult melanocytes in vitro and in vivo [13, 21--‐25]. 
In contrast, loss of Sox9 in the NC  does not lead to general defects in NC--‐derived structures,  
but  specifically  affects  the  development  of  mesectodermal derivatives, such as smooth 
muscle cells and craniofacial bones and cartilage [11,26--‐28]. Furthermore, heterozygous 
mutations in Sox9 in both mice and humans, result in campomelic dysplasia, a syndrome 
associated with dwarfism, skeletal malformations, cleft palate, XY sex reversal and often 
hermaphroditism [28--‐ 30]. However, data on Sox9 expression in melanocytes are inconsistent, 
and a functional implication of Sox9 in melanocyte formation has not been provided so far [23]. 
Based on the assumption that mechanisms of tumor formation might be related to those 
underlying the generation of the cell type, from which the tumor develops, we and others have 
recently addressed the function of Sox10 in melanoma. These studies demonstrated a crucial 
role of Sox10 in the pathogenesis of giant congenital naevi and melanoma in both mice and 
humans by regulating proliferation and survival of melanocytic cells and maintenance of their 
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cellular identity [9; 31]. However, the precise molecular mechanisms mediating Sox10 function 
in melanoma remain to be investigated.  
Here we show that in contrast to Sox10, Sox9 appears to be expressed at very low levels only 
and is functionally not required in melanocyte stem cells, committed melanocytes, and 
melanoma cells. However, Sox9 expression is elevated upon Sox10   deletion   in   mouse   
and   human   melanoma   cells   [9],   and   critically contributes to the anti--‐tumorigenic effects 
observed upon Sox10 inactivation in giant congenital naevus and melanoma. 
Results 
Expression analysis of SOXE factors in human skin melanocytes, giant congenital naevi, 
and primary melanoma in vivo 
While  SOX10  expression  and  function  has  been  well  established  in  adult 
melanocytes, naevi, and melanoma tissue in human and mice [9; 23], studies on SOX9 
expression in melanocytic cells are controversial. SOX9 was reported to be expressed in 
cultured human melanocytes in vitro [32], human melanocytes in vivo [33], and in human 
melanoma [34--‐36]. Other reports, however, failed to reveal Sox9 mRNA and protein expression 
in melanoblasts and differentiated melanocytes during development and postnatally [21,37]. 
Given the close relationship between SoxE factors, one conceivable explanation for these 
discrepancies might be that antibodies raised against a given SoxE protein fail to discriminate 
between SOX9 and SOX10 epitopes. Indeed, when we performed immunohistochemistry on 
murine skin to test the specificity of various anti--‐ SOX9 antibodies, several of them 
recognized both melanocytes and epithelial cells in the outer root sheet (a region in hair 
follicles known to express and functionally  require  Sox9;  [37--‐38]   (Supplemental  Fig. 1). In 
contrast, the antibody sc--‐20095 exclusively detected protein expression in epithelial cells but 
not in melanocytes. Of note, in human melanoma cell lines in vitro, all antibodies tested  but  
sc--‐20095   not  only  recognized  SOX9,  but  also  a  protein  of  the molecular weight of 
SOX10 and detected by a SOX10--‐specific antibody (Supplemental Fig. 2A--‐D). 
To  further  investigate  the  specificity  of  anti--‐SOX9  antibodies,  we  performed SOX10 
knockdown in human melanoma cell lines in vitro and analyzed SOX10 and SOX9 
expression using Western blot analysis (Supplemental Fig. 2E--‐K).  As shown in Supplemental 
Fig. 2E--‐K, different anti--‐SOX9 antibodies used in earlier studies detected SOX10 protein 
expression, which was lost upon SOX10 knock--‐ down. The only anti--‐SOX9 antibody, which did 
not display cross--‐reactivity with SOX10 protein, was sc--‐20095. 
Therefore, we chose to reassess SOX9 expression in human melanocytes and melanocytic 
skin lesions using the specific SOX9 antibody sc--‐20095. Double immunostaining for SOX9 and 
MITF (Microphthalmia--‐associated transcription factor), an established marker of melanocytes 
[39] revealed no detectable SOX9 expression in human skin melanocytes in vivo (Fig. 1A--‐G). In 
contrast, SOX10 was readily detectable in human melanocytes (Supplemental Fig. 3A,B). 
Moreover, while SOX10 was expressed in 100% of human giant congenital naevi, SOX9 
expression was not detected in the same set of patient samples (n=17; (Fig. 1H; Supplemental 
Fig. 3D); [9]). Likewise, all samples of a melanoma tissue microarray composed of 56 primary 
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melanoma biopsies revealed strong SOX10 expression (Fig. 1I; [9]). SOX9 expression, 
however, was found in only 41% (23/56) of the primary melanoma samples, in which it was 
expressed in a few scattered cells accounting for less than 10% of all melanoma cells (Fig. 1I). 
In contrast, expression of SOX9 was readily detectable in the epithelial lineage of normal 
skin as well as in basal cell carcinoma, an epithelial skin cancer (Fig. 1E, F; Supplemental Fig. 
3C; [37,40]). To investigate the mRNA expression of SOX10 and SOX9 in a large set of human 
melanoma samples, we used of the TCGA (The Cancer Genome Atlas) database. Interestingly, 
the vast majority of human melanoma samples displayed much higher SOX10 than SOX9 
expression (Fig. 1J) and only very few samples were characterized by a SOX9 high / SOX10 
low expression  pattern   (Fig.  1K).   Thus,  SOX10   but   not   SOX9   is   prominently 
expressed in normal human melanocytes, human giant congenital naevi, and primary 
melanoma.  
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 Figure  1.  Differential  expression  of  SOX10  and  SOX9  in  human melanocytes, human giant 
congenital naevi and human melanoma samples. A, Scheme showing the localization of epidermal 
melanocytes (in red) in the human skin. B, C, Immunostaining for MITF (green, left panel) and SOX9 
(red, right panel) in the human skin demonstrating the lack of SOX9 expression in the epidermal 
melanocytes. Inserts show higher magnification images of MITF and SOX9 immunostainings. Scale bars, 
25 µm. D, Scheme showing the localization of melanocytes (in red) within the hair follicle. E, 
Immunostaining for MITF (green) and SOX9 (red) in the human skin reveals the expression of SOX9 in 
the cells of outer root sheath but not in the MITF--‐positive melanoblasts/melanocytes. Scale bar 100 µm. 
F, G, High magnification images of immunostaining for MITF and SOX9 in the upper part of human hair 
follicle (F) and the follicular bulb (G). H, Analysis of SOX9 (red, left panel) and SOX10 (red, right panel) 
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expression in the patients with human giant congenital naevi demonstrates the lack of SOX9 expression  
in  the  SOX10--‐positive  giant  congenital  naevi  cells.  Inserts  show higher magnification. I, 
Representative examples of immunostaining for SOX9 (green) and SOX10 (red) in a tissue microarray 
of primary melanoma samples are shown. J--K, Distribution of SOX10 vs. SOX9 expression in human 
melanoma (based on TCGA database). 334 melanoma patients were divided in two groups, namely 
SOX10 High/ SOX9 Low and SOX10 Low / SOX9 high based on SOX10 and SOX9 expression 
levels. DP, dermal papilla; HF, hair follicle; M, melanocytes; ORS, outer root sheath. Scale bars, 25 µm. 
 
SOX10 and SOX9 exhibit divergent functional roles in murine melanocyte stem cells and 
hair pigmentation 
To corroborate our findings in an experimentally amenable system, we extended the analysis of 
Sox9 expression to mouse melanocytes, taking advantage of a previously described iDct--‐GFP 
mouse line (Fig.2A,B; [41]). Doxycycline--‐induced GFP--‐labelled melanocytes were isolated via 
fluorescence--‐activated cell sorting (FACS) and subjected to RNA--‐Seq analysis (Fig.2A). While 
Sox10, Mitf and Tyr were expressed at high levels (Sox10 reads were 1292, 1372, 1776 and 
2488  at E15.5, E17.5, P1 and P7, respectively), the expression of Sox9 was extremely low 
(Sox9 reads were 68, 65, 105 and 128  at E15.5, E17.5, P1 and P7, respectively). These data 
are in accordance with earlier studies on Sox9 mRNA and protein expression in murine 
melanoblasts and melanocytes [21,37] and suggest that in contrast to Sox10, Sox9 expression 
is virtually absent in the melanocytic lineage during mouse embryogenesis and postnatally. 
Melanocyte stem cells are found in a specialized region of the hair follicle called bulge and give 
rise to melanocyte progenitors and differentiated melanocytes [42]. The latter are located in the 
lower hair follicle portion termed bulb, where they  transfer  pigment  to  the  growing  hair.  
When  melanocyte stem  cells  are functionally impaired, they fail to generate melanocytes, 
which results in hair graying [43]. To further investigate the expression of Sox10 and Sox9 in 
the melanocytic lineage of the mouse skin, we made use of Dct::LacZ transgenic mouse line 
expressing LacZ driven by the dopachrome tautomerase (Dct) promoter that allows genetic 
tracking of melanocyte stem cells and their derivatives in the hair follicle (Fig. 2C; [44]). Sox10 
expression was detected in X--‐ Gal--‐positive melanocyte stem cells located in the bulge region 
(Fig. 2E, upper panels) as well as in differentiated melanocytes in the hair follicular bulb (Fig. 
2E,    lower    panels).    Similarly    to    the    situation   in    human    melanocytes, 
immunostaining with the specific anti--‐Sox9 antibody sc--‐20095 demonstrated absence of Sox9 
expression in X--‐Gal--‐positive melanocyte stem cells and their progeny (Fig. 2D, upper and 
lower panels). Sox9 expression was restricted to cells of the epithelial lineage, namely the 
outer root sheath and the epithelial stem cell compartment in the bulge area (Fig. 2D; 
Supplemental Fig. 4), in agreement with previous reports [37,38,45]. 
To address the function of Sox10 and Sox9 in the melanocytic lineage in vivo, we conditionally 
ablated either Sox10 (Fig. 2H) or Sox9 (Fig. 2F) using Tyr--CreERT2 transgenic mice [46] 
carrying floxed alleles of Sox10 [47] and Sox9 [27], respectively. Tamoxifen--‐induced 
homozygous deletion of Sox10 in Sox10fl/fl Tyr-- CreERT2  mice  resulted  in  progressive  hair  
graying,  revealing  an  essential function  of  Sox10  for  melanocyte  stem  cell  
homeostasis  (Fig.  2I,  [23]).  In contrast, homozygous deletion of Sox9 in the melanocytic 
lineage did not cause hair graying even after a prolonged period after tamoxifen--‐induced gene 
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deletion (Fig. 2G). Thus, these two closely related genes are not only differentially expressed 
but also play distinct roles in the biology of melanocytes in vivo. 
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 Figure 2. Sox9 is not expressed in the mouse melanocytic lineage and is not functionally required 
for the maintenance of melanocyte stem cells and melanocytes in the postnatal skin. A, A 
schematic representation of the experimental strategy used to analyze the expression of Sox9, Sox10, 
Mitf and Tyr genes in the melanocytic lineage in vivo. B, Results of RNA--‐seq analysis demonstrating high 
Sox10 and low Sox9 expression in melanocytic cells at various stages of development. C, A schematic 
representation of the anatomical location of the melanocyte stem cells, melanoblasts and differentiated 
melanocytes within the hair follicle in the mouse skin. D, X--‐Gal  staining (blue) combined with Sox9 
immunostaining (red) in skin sections of Dct::LacZ mice demonstrating the lack of the Sox9 expression in 
the melanocyte stem cells located in the bulge region of the hair follicle (upper panels) and in the 
differentiated melanocytes located in the hair follicular bulb (lower panels). E, Skin sections of 
Dct::LacZ mice stained for Sox10 (red) in combination with X--‐Gal staining  (blue)  reveal  the  expression  
of  Sox10  in  the  melanocyte  stem  cells (upper panels) as well as in the differentiated melanocytes 
(lower panels). Dashed lines demarcate HFs. Insets show high magnification views. F--I, Experimental 
strategy used to analyze the effect of the lack of Sox9 (F) and Sox10 (H) expression in the mouse 
melanocytic lineage. Pictures of two representative mice at 6 months of age lacking Sox9 gene (G) and 
Sox10 gene (I) demonstrating the effects on hair graying. Bg, bulge; HF, hair follicle; MSCs, melanocyte 
stem cells; Mo, months; E 15.5, embryonic day 15.5; P0, postnatal day 0; SG, sebaceous gland. Scale 
bars, 25 µm. 
 
Sox10 and  Sox9 are  differentially expressed in  mouse giant congenital naevi and 
melanoma and exhibit functionally distinct roles in tumor initiation 
To functionally assess the role of SoxE factors in melanomagenesis, we first performed 
immunohistochemical staining for Sox9 and Sox10 of giant congenital naevi formed in 
Tyr::NrasQ61K mice and in melanoma derived from giant congenital   naevi   in   
Tyr::NrasQ61KInk4a--/--     mice   [9,48].   In   contrast   to   the widespread expression of Sox10 
displayed by mouse naevi and melanoma tissue (Fig. 3B,D, [9]), immunostaining of both naevi 
and primary melanoma sections did  not  reveal  any  detectable  expression  of  Sox9  protein  
(Fig.  3A,C; Supplemental Fig. 4B), consistent with the data that we have obtained for human 
giant congenital naevi and melanoma (Fig. 1H--‐I). Despite the lack of detectable Sox9 
expression, low levels of Sox9 might be functionally implicated in the formation of melanocytic 
lesions arising in Tyr::NrasQ61K mice. To address this issue, we generated Tyr::NrasQ61K Sox9fl/fl 
Tyr--CreERT2 mice and conditionally deleted both Sox9 alleles by tamoxifen treatment of the 
mice (Fig. 3E). However, skin hyperpigmentation induced by oncogenic NRas was not affected 
in Tyr::NrasQ61K Sox9fl/fl Tyr--CreERT2 mice and was comparable to that presented by their 
control Tyr::NrasQ61K littermates (Fig. 3F). These data reveal that in contrast to Sox10  (Fig.  
3G,H},  Sox9  is  not  required  for  the  formation  of  melanocytic lesions. 
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 Figure 3. Mouse giant congenital naevi and melanoma reveal no expression of Sox9. A--D, 
Immunostaining for Sox9 (A, C) and Sox10 (B, D) in the skin sections of Tyr::NrasQ61K  and 
Tyr::NrasQ61KINK4a--/--  mice.   E--H, Experimental strategy used to abrogate the expression of Sox9 (E) 
and Sox10 (G) in the mouse melanocytic lineage. Pictures of two representative mice 1 year after 
tamoxifen injections reveal no reduction in the skin hyperpigmentation in Tyr::NrasQ61KSox9fl/+Tyr-
-CreERT2 mice as compared to their Tyr::NrasQ61K littermates (F) in contrast to a pronounced skin 
whitening observed upon Sox10 loss (H). BF, bright field; HF, hair follicle; mo, months; P0, postnatal day 
0. Scale bars, 25 µm. 
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Deletion of SOX10 in giant congenital naevus cells results in the induction of SOX9 
expression 
To  gain  insight into  the  possible interplay  between SOX10  and  SOX9  during tumor 
progression, we quantified the expression levels of SOX10 and SOX9 in normal human 
melanocytes, in cells from giant congenital naevi, and in a melanoma cell line (M010817; [49]) 
using quantitative RT--‐PCR analysis (Fig. 4A--‐ C). Notably, NRASQ61K--‐associated tumor 
progression was associated with an increase in SOX10 expression (Fig. 4B). Cells from giant 
congenital naevi showed a 5--‐fold  increase in SOX10 expression when compared to normal 
melanocytes, while   M010817   melanoma   cells   displayed   a   10--‐fold   increase   in   
SOX10 expression when compared to normal melanocytes (Fig. 4B). In striking contrast to the 
increase in SOX10 expression, SOX9 expression levels were low in human melanocytes and 
further decreased with melanoma progression (Fig. 4C). 
To assess whether the disparate expression of SOX9 and SOX10 is a general feature of 
human melanoma samples, we analyzed the endogenous expression of these SOXE proteins 
in a large set of human melanoma cell lines previously categorized into  cells  with  proliferative 
and  invasive signatures,  respectively [49]. Of note, all cell lines with a proliferative signature 
were characterized by high SOX10/low SOX9 mRNA expression (Fig. 4D). However, many cell 
lines with an invasive signature displayed the opposite expression pattern and showed low 
SOX10/high SOX9 mRNA expression. These date were confirmed on the protein level by 
Western blot analysis of several proliferative and invasive cell lines (Fig.4E). 
Interestingly, an inverse correlation between SOX10 and SOX9 expression has previously been 
observed in several systems, including cultured human melanocytes, where upon the induction 
of differentiation, SOX10 levels were reduced concomitantly with an increase in SOX9 levels 
[32]. Thus, high expression of a given SoxE transcription factor might be causative for 
reduced expression of the related SoxE factor. We therefore asked whether deregulation of 
SOX10 leads to changes in SOX9 expression and found a significant upregulation of SOX9 
mRNA expression upon SOX10 knockdown in human giant congenital naevus cells (Fig. 4F--‐H). 
This is in analogy to the upregulation of SOX9 mRNA previously observed in melanoma cells 
upon SOX10 knockdown [9]. Moreover,  SOX10  knockdown  also  resulted  in  upregulation  of  
SOX9  protein levels in human melanoma cells (Supplemental Fig. 5A). The combined data 
indicate that SOX10 normally suppresses SOX9 expression in cells from melanocytic lesions. 
To address whether the findings in human cells in vitro also apply to the in vivo situation in 
mice, we isolated melanocytic progenitors using fluorescence--‐ activated cell sorting (FACS) 
from the skin of Tyr::NrasQ61K and Tyr::NrasQ61K Sox10LacZ/+ mice that lack one allele of Sox10 
(Fig. 4I) and subsequently measured Sox9 expression levels using quantitative RT--‐PCR (Fig. 
4K, L). Elevated Sox10 levels mediated by oncogenic NRas in melanocytic cells from 
Tyr::NrasQ61K mice [9]  were  associated  with  decreased  Sox9  mRNA  expression  as  
compared  to normal   melanoblasts  wild--‐type   for  NRas.   However,  reduced  Sox10  
levels brought about by Sox10 heterozygosity resulted in upregulation of Sox9 expression, as 
revealed by comparing cells from Tyr::NrasQ61K with cells from Tyr::NrasQ61K Sox10LacZ/+ mice. 
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Thus, in cells derived from both human and mouse melanocytic lesions, reduced Sox10 levels 
were accompanied by elevated Sox9 expression. 
 
Figure 4. SOX10 knockdown results in elevated SOX9 expression in mouse and human 
melanocytes.  A, Experimental design used to investigate the level of SOX9 and SOX10 expression in 
vitro. Cultured human keratinocytes, melanocytes, cells derived from biopsies of patients with giant 
congential naevi and melanoma cells (M010817 cell line) were subjected to RNA isolation and 
subsequent Q--‐RT--‐PCR analysis. Keratinocytes were used as a control. B, C, Quantitative real--‐time PCR 
analysis showing the decline of SOX9 expression (C) and increase of SOX10 expression (B) that 
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correlate with the acquisition of malignant state by human NRASQ61K--‐mutated cells. Giant congenital 
naevi and melanoma cells were sequenced to confirm NRASQ61K mutation (data not shown). Data are 
presented as the mean fold change and are normalized over levels found in melanocytes. D, E, 
SOX10 and SOX9 expression in a large set of proliferative and invasive cell lines analysed by gene 
expression using microarrays (D) and Western blot (E) techniques. F, Experimental design used to 
deregulate SOX10 expression in human cells derived from the biopsy of a patient with 
NRASQ61K--‐mutated giant congenital naevus. G, H, Quantitative real--‐time PCR analysis of SOX10 (G) 
and SOX9 (H) expression after the knockdown of SOX10. I, Experimental design used to analyze the 
expression of Sox9 in the melanocytic lineage from Tyr::NrasQ61K    and Tyr::NrasQ61K Sox10LacZ/+ 
mice. K, L, Cells were isolated from the trunk skin of Tyr::NrasQ61K    and Tyr::NrasQ61K  Sox10LacZ/+ 
mice and  stained  for  Melan--‐a  and  c--‐Kit  antibodies.  FACS--‐sorted  cells  were subsequently used 
for the RNA isolation and quantitative real--‐time PCR with primers specific for the coding regions of Sox9 
gene. Data are presented as the mean fold change and are normalized to the control. Kerat, 
keratinocytes; M, melanocytes; Nev, naevus cells; Mel, melanoma cells; KD, knock down. 
 
SOX10 and SOX9 display antagonistic functions in melanoma cells  
Based  on  our  findings  it  is  conceivable  that  increased  levels  of  SOX9  might mediate at 
least some of the anti--‐tumorigenic effects observed upon SOX10 loss--‐ of--‐function in melanoma. 
To address this hypothesis, we overexpressed SOX9 in human M010817 melanoma cells in 
vitro and compared the gene expression profile of these cells with that of SOX10 knock--‐
down melanoma cells, using the parental M010817 cell line as control [9]. Unsupervised 
hierarchical clustering revealed that overexpression of SOX9 led to a gene expression 
profile closely resembling the SOX10 knockdown--‐signature, which included in both conditions 
regulators of cell cycle progression,  apoptosis, and melanocytic and mesectodermal 
differentiation (Fig. 5A). Among others, these data suggest that while SOX10 acts as an 
inhibitor of apoptosis in melanoma cells, SOX9 elicits a proapoptotic response. Similarly, 
SOX10 and SOX9 appear to play antagonistic functions  in  the  regulation  of  the  cell  cycle,  
melanocytic  differentiation, and mesectodermal differentiation (Fig. 5A). 
Notably, SOX9 overexpression resulted in decreased expression of a number of genes 
associated with melanocytic differentiation, such as MLANA, MITF, DCT, TYR, and 
importantly SOX10. To confirm the downregulation of SOX10 upon SOX9 overexpression 
observed in microarray analysis (Fig. 5A) also on the protein level, we performed Western blot 
analysis and observed a pronounced downregulation of SOX10 protein upon SOX9 
overexpression in human melanoma cell lines (Fig. 5B). Moreover, chromatin 
immunoprecipitation assays in human melanoma M010817 cells indicated that SOX9 binds to 
the promoter of SOX10, suggesting a direct regulation of the SOX10 gene by SOX9 (Fig. 5C). 
Thus, whereas SOX10 loss--‐of--‐function leads to increased SOX9 expression (Fig. 4), high levels 
of SOX9 suppress SOX10 expression, revealing cross--‐regulatory interactions between these 
two transcription factors. 
Next, we addressed whether the cross--‐regulation  between SOX10 and SOX9 is functionally 
relevant in human melanoma cells. To this end, we performed RNAi experiments to test 
whether interfering with SOX9 overexpression upon SOX10 knockdown could rescue M010817 
melanoma cells (Fig. 5D--‐F). Using two independent sets of siRNAs, the elevated SOX9 levels 
observed in SOX10 knockdown cells were reverted below control levels by means of 
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concomitant SOX9 knockdown (Fig. 5E). Importantly, both SOX9 gain--‐of--‐function and SOX10 
knockdown  promoted  apoptosis  (Fig.  5F;  Supplemental  Fig.  5B).  However, SOX10  
knockdown  cells  were  rescued  when  SOX9  expression  was simultaneously downregulated, 
resulting in numbers of apoptotic cells comparable to those found in control cells (number of 
Annexin V--‐positive apoptotic M010817 cells: control, 9.95±0.9%; SOX10 siRNA #1, 
19.96±0.13%; SOX10  siRNA #2  18.8±0.49%; combination of  SOX10  siRNA #1/SOX9  
siRNA, 9.45±0.79%; combination of SOX10 siRNA #2/SOX9 siRNA. 10.75±0.4%) (Fig.5F; 
Supplemental Fig. 5B). These data indicate that at least in vitro, SOX9 plays a key role in 
mediating the cellular phenotype obtained in human melanoma cells upon suppression of 
SOX10. 
 
Figure 5. Experimental suppression of SOX9 expression rescues the effects of SOX10 
downregulation in human melanoma cells. A, SOX9 overexpression in human melanoma cells closely 
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resembles the gene expression signature of SOX10 knockdown as revealed by unsupervised hierarchical 
clustering of control M010817  melanoma  cells,  SOX9  overexpressing  M010817  cells  and  SOX10 
knock down M010817 cells. Microarray gene expression accession number: GSE37059. B, Western blot 
analysis showing that SOX10 expression is downregulated upon overexpression of SOX9 in two 
independent human melanoma cell lines (A375 and M010817). C, Chromatin immunoprecipitation assay 
demonstrating the binding of SOX9 to the promoter of SOX10 in human melanoma M010817 cells. D, 
E, Quantitative real--‐time PCR analysis of SOX10 (E) and SOX9 (F) expression after the knockdown of 
SOX10 and after the double knockdown of SOX10 and SOX9 in M010817 cell line. F, Quantification of 
number of  Annexin  V--‐positive   cells  based  on  the  FACS  analysis  in  the  melanoma M010817 
cells upon SOX9 KD, SOX10 KD or double SOX9/SOX10 KD.   OE, overexpression; KD, knock down; 
ChIP, chromatin immunoprecipitation; prom, promoter. 
 
Deletion of Sox9 rescues the phenotype of Tyr::NrasQ61KSox10fl/+Tyr--‐ CreERT2 mice, 
restoring NrasQ61K--‐mediated naevus formation 
As in human melanoma cells in vitro, reducing Sox10 levels in vivo elicits an anti--‐tumorigenic 
effect, preventing melanocytic hyperplasia in Tyr::NrasQ61KSox10fl/+Tyr--CreERT2 mice [9]. To 
functionally test whether upregulation of Sox9 is the key factor accountable for the lack of 
hyperplasia in these  mice  in  vivo,  we  performed  simultaneous  conditional  ablation  of  both 
Sox10 and Sox9 genes in the Tyr::NrasQ61K  mice (Fig. 6A, B). In agreement with our 
previous observations [9], the skin of the snout, paws and the back was noticeably lighter in 
color in Tyr::NrasQ61KSox10fl/+Tyr--CreERT2 mice as compared to their control Tyr::NrasQ61K 
littermates (Fig. 6A, left and middle panels). In contrast,  macroscopic examination of  the  skin  
of Tyr::NrasQ61KSox10fl/+Sox9fl/flTyr--CreERT2 animals showed pronounced hyperpigmentation, 
a hallmark of the skin phenotype found in Tyr::NrasQ61K mice (Fig. 6A, right panels). Thus, 
conditional deletion of Sox9 rescued the effect of Sox10 haploinsufficiency in Tyr::NrasQ61K 
mice. 
As shown in Figure 2, conditional ablation of both alleles of Sox10 in the normal melanocytic 
lineage using Tyr--CreERT2 resulted in loss of functional melanocytes and   hair   graying   (Fig.   
2I).   Likewise,   homozygous   deletion   of   Sox10   in Tyr::NrasQ61K mice not only prevented 
NrasQ61K--‐stimulated skin hyperpigmentation,  but  also  led  to  hair  greying  in  these  mice  
(Fig.  6B,  left panels). To determine whether these phenotypes involve Sox9 activity and 
whether, therefore, loss of Sox9 could rescue the effects of homozygous Sox10 deletion, we 
generated Tyr::NrasQ61KSox10fl/flSox9fl/flTyr--CreERT2 animals. Surprisingly, loss of Sox9 in 
Sox10 homozygous conditional knock--‐out animals efficiently restored skin hyperpigmentation 
as seen on the snout and paws of Tyr::NrasQ61KSox10fl/flSox9fl/flTyr--CreERT2  animals  when  
compared  to  mice lacking Sox10 but not Sox9 in the melanocytic lineage (Fig. 6B, right 
panels). 
We have previously demonstrated that skin hyperpigmentation in Tyr::NrasQ61K mice is due to 
hyperplasia of ectopically located pigment cells emerging in the dermis, around the upper part 
of the hair follicle [9]. To measure the degree of hyperpigmentation in Tyr::NrasQ61K mice with 
conditional Sox10 deletion (heterozygous and homozygous) versus mice simultaneously 
lacking both Sox9 alleles and one or both Sox10 alleles in the melanocytic lineage, we 
quantified the percentage of hair follicles associated with ectopically located melanocytic cells 
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in the back skin of these mouse lines. In Tyr::NrasQ61K mice, more than 90% of all hair follicles 
displayed ectopic pigment cells (Fig. 6D). In contrast, in the absence of one or both alleles of 
Sox10, there were almost no hair follicles with ectopic pigment cells, despite NrasQ61K  
expression (Fig. 6C, D). Strikingly, however, the percentage of hair follicles associated with 
ectopic melanoblasts in Tyr::NrasQ61KSox10fl/+Sox9fl/flTyr--CreERT2 animals was reverted to 
numbers similar to those found in Tyr::NrasQ61K mice (93±1.8% and 96±1%, respectively) (Fig. 
6C, D). Moreover, even in the absence of both Sox10 alleles, loss of Sox9 rescued the 
NrasQ61K–dependent appearance of melanocytic cells found outside hair follicles (93.5±3%) 
(Fig. 6D). These data reveal a key role of Sox9 in preventing melanoma initiation and provide 
novel insights into the functional interplay between Sox10 and Sox9 during melanoma 
formation. 
 
Figure 6. Homozygous deletion of Sox9 rescues the effects of Sox10 loss in Tyr::NrasQ61K mice 
and restores hyperpigmentation in vivo.    A, B, Representative pictures of back skin, paws and 
snouts from mice of the indicated genotypes.  C, D, Histological evaluation of the hyperpigmentation 
phenotype in the skin. Haematoxylin and eosin staining of back skin (C) was followed by the 
quantification (D) of the percentage of hair follicles associated with the hyperpigmentation. HF, hair 
follicle; H&E, haematoxylin and eosin. 
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Discussion 
Our  study  identifies  the  structurally  related  transcription factors  SOX10  and SOX9 as 
functionally antagonistic regulators of postnatal melanocyte and melanoma development. 
Although we did not find SOX9 to be expressed in the melanocytic lineage when SOX10 is 
present, SOX9 expression becomes evident upon SOX10 inactivation in naevus and 
melanoma cells. In this context, SOX9 appears to promote the major cellular processes 
induced by SOX10 loss--‐of--‐ function, namely stop of proliferation and apoptosis. Intriguingly, 
SOX9 and SOX10 are engaged in a cross--‐regulatory feedback loop whereby SOX9, which is 
induced upon SOX10 inactivation, itself suppresses SOX10, thus strengthening an anti--‐
tumorigenic program. 
In many cell lineages and tissues, SOX10 and SOX9 are co--‐expressed and functionally 
redundant [50]. We propose that this is not the case in melanocytic cells and that SOX9, 
unlike SOX10, is neither required for normal melanocyte stem cell homeostasis nor for 
formation of congenital nevi and primary melanoma. Our findings disagree with some 
previously published studies reporting SOX9 expression in the normal and tumor--‐associated 
melanocytic lineage [32--‐34,36,51]. However, as we demonstrate here, most previously used 
anti--‐SOX9  antibodies display  cross--‐reactivity  with  SOX10,  owing  to  the  close relationship 
between these two SoxE factors. Having identified anti--‐SOX10  and anti--‐SOX9  specific 
antibodies, we reveal virtually exclusive expression patterns of these transcription factors in 
the normal human skin and in a large set of melanoma biopsies and cell lines. While SOX10 
expression is restricted to neural crest derivatives, including melanoblasts, differentiated 
melanocytes, and virtually all human naevus and melanoma biopsies tested (Fig. 1; 
Supplemental Fig. 3; [9], SOX9 expression in melanocytic cells was restricted to few scattered 
cells in a subset of melanoma biopsies. In contrast, SOX9 was strongly expressed in epithelial 
cells of the hair follicle, which are devoid of SOX10 expression. 
In support of these data, Sox10 protein expression in the mouse skin is detected in vivo 
throughout all stages of melanocyte development from stem cells to differentiated melanocytes 
in the hair follicular bulb (Fig. 2). Mice lacking Sox10 in the melanocyte lineage display hair 
graying, indicating that Sox10 is necessary for maintenance of melanocyte stem cells and 
committed melanoblasts [23] (Fig. 2). Likewise, Sox10 is required for the establishment of giant 
congenital naevi as well as melanoma [9]. In contrast, murine Sox9 appeared not to be 
expressed in melanocytic cells of the normal skin, nevi, and primary melanoma, while it was 
readily detectable in epithelial cells in accordance with previous reports [33,37,38]. Importantly, 
loss of function analyses failed to reveal a crucial role of Sox9 in normal melanocytes, as 
conditional deletion of Sox9 did not affect generation and long--‐term maintenance of 
melanocytes in vivo and did not result in hair graying, a phenotype characteristic for the loss of 
Sox10. Likewise, lack of Sox9 did not prevent emergence of melanocytic lesions induced by 
oncogenic NRasQ61K  (Fig. 3). These data demonstrate that Sox10 and Sox9 are not only 
expressed in different cellular compartments in the skin, but also play distinct roles in normal 
and transformed melanocytes. 
In cell types other than melanocytes Sox9 and Sox10 can act redundantly. For instance, in 
oligodendroglial progenitors, concomitant expression of Sox9 can compensate for the loss of 
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Sox10 [52,53]. Similarly, in avian and Xenopus embryos, Sox9 and Sox10 are co--‐expressed  
in premigratory neural crest cells and are both able to induce ectopic neural crest cell 
formation upon forced expression in chicken neural tube [11,24,54]. In addition, the two factors 
are able to cross--‐regulate each other at this early stage of neural crest formation. Interfering 
with Sox10 function leads to inhibition of Sox9 expression [55], suggesting that Sox10 is 
required for the expression of Sox9 in pre--‐migratory neural crest. On the other hand, Sox9 
overexpression in Xenopus embryos leads to upregulation of Sox10 expression [24], 
suggesting that Sox9 can also act upstream of Sox10. As development proceeds, however, 
Sox10 expression persists in the trunk neural crest and is downregulated in cranial neural 
crest cells giving rise to mesectodermal structures, while Sox9 expression is absent in trunk 
neural crest cells but present in the cranial neural crest [24,26]. These divergent  expression  
patterns  are  established  by  signaling  pathways differentially regulating transcription of Sox9 
and Sox10, respectively. In particular, TGFβ (transforming growth factor β) simultaneously 
triggers induction of Sox9 and reduction of Sox10 expression [56]. Accordingly, mice lacking 
Sox10 display phenotypes that are distinct from those obtained upon loss of Sox9 [13,54,56--‐58]. 
In particular, Sox10 but not Sox9 is expressed in and required for the generation of 
melanoblasts during mouse embryogenesis [13,21]. Finally, in agreement with our 
expression studies on human skin, humans carrying mutations in SOX9 display campomelic 
dysplasia affecting the skeleton and reproductive system but not melanocytes, whereas 
patients with mutations in SOX10 often exhibit pigmentary anomalies [20,50,59]. 
However, the divergent functions of Sox10 and Sox9 in the skin appear not to be simply due to 
their differential expression patterns. Depending on the cellular context, these two transcription 
factors can also elicit different responses in one and the same cell lineage rather than playing 
redundant roles. Studies in Xenopus embryos demonstrated that while expression of Sox10 at 
the two--‐cell stage was sufficient to activate the expression of Trp--‐2 (Dct) and the induction of 
melanocytic precursors, the expression of Sox9 failed to do so [24]. In mice, loss of  Sox9  
promotes  apoptosis  and  other  phenotypes  in  neural  crest  cells,  but Sox10 is maintained in 
these cells and cannot rescue the Sox9--mutant phenotype [54]. Moreover, while Sox9 activates 
the expression of genes involved in the induction of osteochondrogenesis in neural crest cells 
in pharyngeal arches [26,28,60], Sox10 is involved in the specification of a glial and 
melanocytic gene expression program [13]. In this context, Sox10 and Sox9 play antagonistic 
roles, in that Sox9 promotes cells cycle exit and mesenchymal fates, while Sox10 activates 
proliferation and suppresses mesenchymal fate acquisition [56]. Accordingly, Sox10 
inactivation results in induction of Sox9--‐dependent  fates in postmigratory neural crest cells. 
This interplay between Sox10 and Sox9 functions during normal neural crest development is 
highly reminiscent of our findings in melanocytic lesions, where Sox10 also promotes 
proliferation and survival,  while  Sox9  counteracts  these  cellular  processes.  Indeed,  in  
human melanoma cells, loss of SOX10 not only resulted in upregulation of SOX9 expression, 
but also in global transcriptional changes highly similar to the changes  observed  upon  SOX9  
overexpression  (Fig.  5),  indicating  that  these factors appear to play opposing functions in 
melanoma. Interestingly, a study by Passeron et al. revealed that overexpression of SOX9 
prevents melanoma formation [35] by increasing the expression of the CDK inhibitor p21 and 
subsequent cell cycle arrest. Likewise, a recent report by Pavan and colleagues established 
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that the expression of p21 and p27 were increased upon SOX10 knockdown [31]. Thus, our 
data might provide one explanation for the anti--‐ tumorigenic effect of SOX9, namely by 
downregulation of SOX10. This is in accordance with our previously published results on the 
essential role of SOX10 for melanoma initiation and progression [9]. Of note, the anti--‐
tumorigenic effect elicited by suppressing SOX10 was abolished by concomitant SOX9 
inactivation both   in   human   melanoma   cells   as   well   as   in   mice.   Thus,   antagonistic 
SOX10/SOX9 constitutes a key node in the genetic network underlying melanomagenesis.  
Nonetheless,  it  is  conceivable  that  further  cues  mediate SOX10--‐pro--‐ and SOX9--‐anti--‐
tumorigenic effects, respectively. Moreover, our data do not exclude a role of SOX9 at later 
stages of melanoma disease progression, in particular during metastasis formation by invasive 
cells. Indeed, while we could attribute a SOX10 high/SOX9 low signature to proliferative 
human melanoma cell  lines  and  to  all  human  and  murine  melanoma  tissues  analyzed,  
several human melanoma cell lines reported to display invasive features [49] exhibited SOX10 
low/SOX9 high expression. Although this remains to be shown, these invasive cell lines with 
SOX10 low/SOX9 high expression might have been established  by  capturing  or  inducing  
invasive  tumor  cells  that  appear  to  be rather rare in biopsies of bulk tumor tissue. Likewise, 
apart from experimentally reducing SOX10 levels, other stimuli such as UV exposure might also 
lead to upregulation of SOX9 [51]. In any case, our discovery of the antagonistic interaction 
between SOX10 and SOX9, together with the further characterization of their mode of action in 
melanoma cells, might not only provide new mechanistic insights into how SoxE group proteins 
are regulated and act in the context of melanoma initiation and maintenance, but might also 
point to novel strategies for melanoma therapies. 
 
Materials And Methods 
 
Human Specimens 
All analyses involving human skin, giant congenital naevi and melanoma tissue were performed 
in accordance with the ethical committee in canton Zurich, Switzerland. TMA containing 
melanoma tissue was constructed as previously described [61]. 
Mice 
Tyr::NrasQ61K  [48] were provided by F. Beermann (EPFL Lausanne, Switzerland). Dct--LacZ 
mice were described previously [44]. Sox10fl/fl mice were described previously [47]. Sox9fl/fl  
mice [27] were a kind gift from G. Scherer (Institute of Human Genetics, Freiburg, Germany). 
Tyr--CreERT2 line [46] was provided by L. Chin  (The  University of  Texas  MD  Anderson  
Cancer  Center,  Houston,  Texas, USA). Rosa26--lacZ mice were obtained from Jackson 
laboratory.   All animal experiments were performed in accordance with Swiss law and have 
been approved by the veterinary authorities of Zurich. 
Tamoxifen injections 
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Mice were subjected to intraperitoneal injections of tamoxifen (T5648, Sigma), diluted with the 
mixture of ethanol and sunflower oil (1:9 ratio). Tamoxifen was injected for 5 consecutive days. 
Histological analysis and immunohistochemistry 
Immunohistochemistry on paraffin sections was performed as previously described [9]. Briefly, 
skin samples were fixed in 4% buffered paraformaldehyde and embedded in paraffin. For 
immunohistochemistry, antigen retrieval was performed in citrate buffer (pH 6.0) for 10 minutes 
at 110°C in HistoPro (Rapid Microwave Histoprocessor, Milestone, USA). The following primary 
antibodies were used: anti--‐Sox10  (goat, 1:200, Santa Cruz Biotechnology, Santa Cruz, CA), 
anti--‐Sox10 (mouse, 1:200, R&D), anti--‐Sox9 (rabbit, 1:100, sc--‐20095, Santa Cruz Biotechnology, 
Santa Cruz, CA), anti--‐Sox9 (rabbit, 1:100, ab36748, Abcam), anti--‐ Sox9  (M00006662,  
Abnova),  anti--‐Sox9   (AB5535,  Millipore),  anti--‐Sox9   (GTX 109661, GenTex), anti--‐MITF  
(mouse, clone 6D3, 1:500) was a kind gift from Heinz Arnheiter (NIH, USA). Images were 
captured with a Leica DMI 6000B Microscope and using LAS AF (Leica Application Suite 
Advanced Fluorescence) software. For whole mount X--‐Gal staining, skin samples were fixed 
with 4% buffered paraformaldehyde, washed with PBS and subjected to X--‐Gal staining solution 
overnight at 37°C. After several washing steps, tissue was paraffin embedded and sectioned. 5 
µm thick sections were further counterstained with eosin solution and mounted. 
RNA isolation, reverse transcription and quantitative PCR. 
Total RNA was isolated using Trizol according to manufacturer’s instructions (Invitrogen). 1 μg 
aliquots of RNA were reverse transcribed with Reverse Transcription System (Promega) 
according to the manufacturer's instructions. Data collection and analysis were performed by 
ABI Viia7 Fast Real--‐Time  PCR Systems (Applied  Biosystems). Gene  expression values  of  
averaged  triplicate reactions were normalized to RPL28 expression levels. RPL28 primers are 
as follows: 5’--‐GCAATTGGTTCCGCTACAAC--‐3’ and 5’--‐TGTTCTTGCGGATCATGTGT--‐3’. The 
expression of SOX10 and SOX9 was measured using primers purchased from QIAGEN: SOX10 
(Hs_SOX10_1_SG); SOX9 (Hs_SOX9_1_SG). 
Sequencing 
Cells  derived  from  patients  with  giant  congenital  naevi  were  sequenced  for NRAS. 
Primers for sequencing for Exon 1 (mutation G12) and Exon 2 (mutation Q61K) of NRAS gene 
were as follows: NRAS_1F 5’--‐ATAGAAAGCTTTAAAGTACTG--‐3’ and NRAS_1R 5’--‐
TTCCTTTAATACAGAATATGG--‐3’, NRAS_2F 5’--‐ CCCCTTACCCTCCACAC--‐3’ and NRAS_2R 5’--‐
AACCTAAAACCAACTCTTCCCA--‐3’. 
Cell culture and transfection assays 
Silencing RNA (siRNA) transfection was carried out using INTERFERin transfection solution 
according to the manufacturer’s protocol (Polyplus--‐ transfection, Illkirch, France). Cells were 
transfected with 10 nM of siRNA (Qiagen) for 96 hours before RNA was extracted or used for 
FACS analysis. As control siRNA, the  All--‐Star  negative siRNA sequence (Qiagen) was  
used, and gene--‐specific  siRNAs targeting siSOX10 (SI00729414, SI00729421) and siSOX9 
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(SI00007595, SI00007609) were obtained from Qiagen. Transfection of DNA was carried using 
JetPEI transfection solution according to the manufacturer’s protocol (Polyplus--‐transfection,  
Illkirch, France). Cells were transfected with 1 ug of pCMV6--‐SOX9  (Origene SC321884) or 
empty vector for 96 hours before RNA was extracted or used for FACS analysis. 
Melanocyte FACS and RNA seq 
Melanocytes were purified by FACS from doxycycline--‐treated  iDct--‐GFP  mice as previously 
described [41]. Total RNA was prepared from FACS--‐sorted cell fractions containing GFP--‐
positive melanoblasts/melanocytes according to standard Illumina RNA--‐Seq paired--‐end 
protocol and sequenced on the Illumina GAIIx to 80 bp per read. 
Microarray analysis 
Total RNA was isolated from melanoma cell cultures using TRIzol according to the  
manufacturer’s  instructions  (Invitrogen).  Total  RNA  was  amplified  and biotin--‐labelled  
using the Message Amp II--‐Biotin  Enhanced aRNA Amplification Kit (Ambion, Austin, TX, 
USA). Biotin--‐labelled RNA was hybridized to Affymetrix HG--‐U133 plus 2.0 oligonucleotide 
microarrays following the manufacturer’s protocol  (Affymetrix,  Santa  Clara,  CA,  USA).  After  
hybridization,  microarrays were washed and stained using a GeneChip Fluidics Station 450 
(Affymetrix) and then  scanned  using  a   GeneChip  Scanner  7G  (Affymetrix).  Raw   data  
was processed by R using the affycoretools package (RMA). Gene expression datasets for   
SOX10   knockdown   were   obtained   from   NCBI   GEO   GSE37059.   Gene expression 
analysis was performed by R using the limma package. P--‐values were adjusted by FDR p--‐value 
adjustment. For melanoma cell lines analysis (proliferative vs invasive): Normalized expression 
values were downloaded from GSE4840 containing microarray data for twenty three melanoma 
cell cultures. Pearson’s product moment correlation (r) was  calculated for the SOX10 
andSOX9 expression values across all twenty three samples. P--‐value was determined from the 
t statistic calculated from r. 
Flow cytometry and cell sorting 
Skin tissue (from back skin) was digested with a mixture of Dispase (Roche) and Collagenase I 
(Worthington) for 1 hour at 37°C and enzymatic reaction was stopped by addition of DMEM 
media supplemented with 10%FCS as previously described [9]. Subsequently, single cell 
suspension was filtered through 40 µm strainers (BD). For cell cycle analysis, Click--‐iT® EdU 
Alexa Fluor® 647 Flow Cytometry Assay Kit (Invitrogen) was used. Cells were labeled with PI 
according to   manufacturer’s  protocol  and   DNA   content   was   measured  using   a   BD 
FACSCanto II flow cytometer (BD Biosciences) and a BD FACSDiva software (BD 
Biosciences). For measurement of apoptosis, Annexin V--‐PE Apoptosis Detection Kit I (BD 
Pharmingen, 559763) was used. FACSAria sorter and FACS DiVa software (BD Biosciences) 
were used for cell sorting. 
Chromatin Immunoprecipitation 
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ChIP analysis was performed as previously described [62]. Sox9 antibody was from Santa 
Cruz Biotechnology (sc--‐20095, Santa Cruz Biotechnology). SOX10 promoter sequences were 
amplified with forward primer (5’--‐ CCTCTGCCTCGTGTGACTAC--‐3’) and reverse primer (5’--‐ 
TCCTGTCTGGAGTGGGCTG--‐3’). 
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Supplementary Figure 1. Immunohistochemical analysis of the cross-- reactivity of anti--Sox9 
antibodies to Sox10 in the mouse skin. A--D, Immunostaining for Sox9 (red) using different anti--‐Sox9 
antibodies, namely anti--‐ Sox9 from Santa Cruz (A), Millipore (B), Abcam (C) and Abnova (D). E, Summary 
of immunohistochemical analysis using anti--‐Sox9 antibodies from different sources. ORS, outer rooth 
sheath; M, melanocytes. 
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 Supplementary Figure 2. Assessing the cross--reactivity of anti--SOX9 antibodies to SOX10.  A--D, 
Western blots demonstrating the cross--‐reactivity of anti--‐SOX9 antibodies (Abcam, Abnova and Millipore) 
to SOX10 and specificity to SOX9 (A--‐D). E, A schematic illustration of the experiment used to test anti--‐
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SOX9 antibodies. F--‐K, Western blots demonstrating the cross--‐reactivity of anti--‐SOX9 antibodies using 
protein homogenates isolated from melanoma cells transfected with either sh control or sh SOX10 
vectors. 
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Supplementary  Figure  3.  SOX10  and  SOX9  expression  in  human melanocytic and epithelial 
lineages.   A, A schematic representation of the location of melanocytes in the hair follicular bulb. B, 
SOX10 expression in the hair  follicular    bulb.  C,  SOX9  expression  in  human  basal  cell  
carcinoma.  D, Analysis of the expression of SOX10 and SOX9 in the human giant congenital naevi 
(patient H08 10533). Adjacent sections were stained with anti--‐SOX10 and anti--‐SOX9 antibodies. Note 
the positive staining for SOX9 in the hair follicle. BCC, basal cell carcinoma; GCMN, giant congenital 
melanocytic naevi; M, melanocytes. 
 
 
Supplementary Figure 4. Sox9 is not expressed in murine melanocytes and cells of giant 
congenital naevi in the postnatal mouse skin. A, Bright field picture (left panel) showing the 
pigmented melanocytes located in the hair follicular bulb. Immunostaining for Sox9 (red) demonstrating 
that Sox9 is expressed in the epithelial cells of the hair follicle (outer root sheath) but not in the 
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pigmented melanocytes. B, Immunostaining for Sox9 (red) demonstrating the expression of Sox9 in 
the outer rooth sheath and the absence of Sox9 expression in the cells of giant   congenital naevi in 
Tyr::NrasQ61K  mouse.   BF, bright field; HF, hair follicle, M, melanocytes; ORS, outer root sheath. 
 
 
Supplementary Figure 5. SOX9 and SOX10 play antagonistic roles in human melanoma cells. A, 
Western blot analysis demonstrating that SOX9 expression is upregulated upon SOX10 knockdown in 
human melanoma cell lines. B, FACS analysis of apoptosis in M010817 melanoma cell line. M010817 
control cells, M010817 SOX10 KD cells, M010817 SOX9 OE and M010817 SOX10 KD SOX9KD cells 
were analyzed for the number of Annexin V--‐positive cells. KD, knockdown; OE, overexpression. 
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7. Methylation dependent SOX9 expression mediates invasion in 
human melanoma cells and is a negative prognostic factor in 
advanced melanoma 
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Abstract 
Background 
Melanoma is the most fatal skin cancer displaying a high degree of molecular heterogeneity. 
Phenotype switching is a mechanism that contributes to melanoma heterogeneity by altering 
transcription profiles for the transition between states of proliferation/differentiation and 
invasion/stemness. As phenotype switching is reversible, epigenetic mechanisms, like DNA 
methylation, could contribute to the changes in gene expression.  
Results 
Integrative analysis of methylation and gene expression datasets of five proliferative and five 
invasion melanoma cell cultures revealed two distinct clusters. SOX9 was methylated and lowly 
expressed in the highly proliferative group. SOX9 overexpression resulted in decreased 
proliferation but increased invasion in vitro. In a B16 mouse model, sox9 overexpression 
increased the number of lung metastases.  Transcriptional analysis of SOX9-overexpressing 
melanoma cells revealed enrichment in epithelial to mesenchymal transition (EMT) pathways. 
Survival analysis of the The Cancer Genome Atlas melanoma dataset showed that metastatic 
patients with high expression levels of SOX9 have significantly worse survival rates. Additional 
survival analysis on the targets of SOX9 revealed that a majority of SOX9 down-regulated 
genes have survival benefit for metastatic patients. 
Conclusions 
Our genome wide DNA methylation and gene expression study of 10 early passage melanoma 
cell cultures revealed two phenotypically distinct groups. One of the genes regulated by DNA 
methylation between the two groups was SOX9. SOX9 induces melanoma cell invasion and 
metastasis and decreases patient survival. A number of genes down regulated by SOX9 have a 
negative impact on patient survival. In conclusion, SOX9 is an important gene involved in 
melanoma invasion and negatively impacts melanoma patient survival. 
 
Keywords: melanoma, DNA methylation, phenotype switching, SOX9, invasion 
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Introduction 
 
Melanoma is an aggressive skin cancer that originates from melanocytes, i.e. pigment cells that 
reside in the basal layer of the epidermis and are derived from the neural crest during early 
development [1]. It is the most life-threatening neoplasm of the skin and is considered a major 
health problem due to rising incidence and mortality rates [2, 3]. Melanoma is a tumor with a 
high degree of heterogeneity and this phenotypic heterogeneity is reversible [4-7]. In addition to 
being a challenge for basic research, melanoma plasticity is a major hurdle for successful 
treatment [8]. Investigating the molecular basis of phenotypic heterogeneity is crucial to better 
understand melanoma progression and should provide useful insights for the development of 
more effective therapies. 
  
In an effort to elucidate the molecular mechanisms of melanoma progression, significant 
differences have been detected between melanoma cells from the same lesion [4, 6, 9]. We and 
others have found that melanoma cells generally express two distinct gene expression 
signatures, that these signatures correlate with in vitro characteristics and these phenotypes are 
reversible depending on their cellular microenvironments [10-12]. One signature is 
characterized by the upregulation of several melanocytic genes like MITF, TYR, and DCT. 
These melanoma cells are highly proliferative and weakly invasive in vitro and so are named the 
proliferative phenotype. The other signature is characterized by the upregulation of many 
mesenchymal genes such as WNT5A, TGFβ, and FGF2. In contrast to the proliferative cells, 
these cells are highly invasive but have a low proliferative capacity in vitro and are thus named 
the invasive phenotype. Meta-analysis of all available melanoma microarray datasets available 
on the NCBI GEO database confirmed these two gene signatures in 86% of the 536 melanomas 
[13]. Immunohistochemical analyses for MITF and WNT5A, markers of the proliferative and 
invasive phenotype respectively, of human primary and metastatic melanomas displayed an 
anti-correlative staining pattern confirming that these phenotypes exist in vivo [14]. Together 
these findings culminated in the phenotype switching model for melanoma progression, in which 
melanoma cells respond to changing microenvironmental signals, such as hypoxia, by 
reprogramming their gene expression patterns to switch between states of proliferation and 
invasion [15] [9]. Thus, phenotype switching has important implications in melanoma 
progression. Invasive phenotype cells characterized by low MITF expression, have stem-like 
properties [16], including the ability to initiate tumors with high efficiency [17]. Consequently, 
tumors comprise a mix of MITF-positive and negative melanoma cells [18].  
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 DNA methylation provides a stable and heritable gene regulatory mechanism for which 
melanoma cells could alter the expression of many genes [19]. Aberrant DNA methylation is a 
mechanism known to cause tumorigenesis [20]. Tumor suppressor genes become silenced by 
hypermethylation of their promoter region, thus promoting tumorigenesis. Global 
hypomethylation has been observed in many cancers including melanoma to decrease with 
progression of the disease [21-23]. DNMT3a and DNMT3b, the de novo DNA 
methyltransferases, were shown to have increased expression in metastatic melanomas 
compared to primary melanomas [24]. Another group showed that DNMT3a is required for 
melanoma development and metastasis in a melanoma mouse model [25]. Several signaling 
pathways have been shown to be deregulated as a result of aberrant DNMT-dependent 
methylation in melanoma, which include MAPK, WNT, PI3K, pRB, and pathways in cell cycle, 
apoptosis, invasion and metastasis [26]. Progressive global DNA hypomethylation has been 
observed in malignant  melanocyte transformation, and surprisingly transformation was blocked 
in the presence of 5-Aza-2-deoxycytidine (Decitabine, Aza), a DNMT inhibitor [22]. It would 
suggest that targeted hypomethylation is required for malignant transformation and not overall 
global hypomethylation caused by Aza treatment. This is supported by our observation that 
treating proliferative melanoma cells with Aza had no measureable effect on their invasive 
abilities (data not shown). 5-Aza-2-deoxycytidine treatment of various melanoma cell lines was 
shown to increase SOX9 expression and induce expression of p27 and p21 [27].  SOX9 is a 
transcription factor involved in neural crest specification [28] and SOX9 overexpression in 
melanoma cell lines have been shown to induce cell cycle arrest in a p21 dependent manner 
[29]. Taken together, it would suggest that DNA methylation has a crucial role in malignant 
transformation and progression by altering the landscape of the methylome to promote tumor 
progression, and SOX9 is one of the targets of DNA methylation that induces cell cycle arrest. 
In this study, we examine the expression of the DNMTs between the proliferative and invasive 
melanoma cell cultures and describe the differential melanoma methylome by MeDIP-chip. We 
confirm that SOX9 expression is regulated by DNA methylation and has a role in cell cycle 
regulation, invasion in vitro and in vivo and could be a prognostic marker for overall survival in 
metastatic melanoma patients.  
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Results 
Proliferative melanoma cells have higher levels of global DNA-methylation 
We have previously established melanocytic markers like MLANA to distinguish between the 
proliferative and invasive phenotype on a cohort of primary melanoma cell cultures [11, 30] 
(Supplemental Figure 1). To investigate if methylation differences exist between the proliferative 
and invasive melanoma phenotypes, we compared five proliferative (i.e. M000921, M010817, 
M080423, M980513, M050829) and five invasive (i.e. M990115, M010119, M080201, M080307, 
M080310) melanoma cell cultures for expression of de novo DNA methyltransferases DNMT1, 
3a, and 3b (Figure 1A). We observed that the invasive phenotype melanoma cell cultures had 
about 51.1% less expression of DNMT1 as compared to the proliferative phenotype melanoma 
cell cultures (Figure 1A). DNMT3b had about 50% less protein expression in the proliferative 
melanoma cell cultures compared to the invasive melanoma cell cultures (Figure 1A). However, 
DNMT3a was not differentially expressed between the proliferative and invasive phenotype 
(Figure 1A). Global methylation analysis by methyl-cytosine ELISA showed that the invasive 
phenotype cells have significantly less DNA methylation in their genome compared to the 
proliferative phenotype cells, 13.0% to 20.9% respectively (Figure 1B). This raises the possibility 
that differential methylation exists between the proliferative and invasive phenotype.  
 
A 73-gene signature is significantly differentially methylated and expressed in 
proliferative melanoma cells 
The difference in global methylation levels and protein expression of DNMT1 and DNMT3b 
prompted us to investigate the methylation profiles of the proliferative and invasive phenotype 
melanoma cells. To determine which CpG islands were differentially methylated between the 
proliferative and invasive phenotypes, we immunoprecipitated methylated DNA from five 
proliferative and five invasive melanoma cell cultures by MeDIP [31] followed by hybridization to 
Nimblegen Human DNA Methylation 3x720K CpG Island Plus RefSeq Promoter Arrays. This 
array contains 720,000 probes for 22,532 promoter regions and 27,728 CpG islands. We 
calculated the differential methylation levels between the five proliferative and five invasive 
melanoma cells with a sliding window ANOVA test with the R package DMR supplied from 
Nimblegen. We found 406 gene promoters to be significantly and differentially methylated 
between the proliferative and invasive phenotypes (Figure 1C). 320 promoter regions were 
hypermethylated in the proliferative phenotype and 86 promoter regions were hypermethylated 
in the invasive phenotype. The greater number of hypermethylated regions in the proliferative 
phenotype would be consistent with the global methylation data.  
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 Gene expression data for the 10 melanoma cell cultures previously generated by us [13] were 
reanalyzed for differential gene expression between the proliferative and invasive phenotypes 
using the R package limma [32]. A total of 1750 genes were differentially expressed between 
the proliferative and invasive phenotype (Fold Change > 2, FDR corrected p < 0.05) (Figure 
1D). We then analyzed the relationship between the promoter methylation status and mRNA 
expression levels for all genes in both datasets. Genes were filtered for a peak score > 2 for 
methylation, fold change > 2 for gene expression and an FDR-corrected p-value < 0.05. A total 
of 73 genes showed both significant differential DNA methylation and significant differential 
expression between the proliferative and invasive phenotype (Supplemental Table 1). 62 genes 
from the proliferative phenotype had hypermethylated promoters and low RNA expression and 
11 genes in the invasive phenotype had hypermethylated promoters and low RNA expression 
as compared to the proliferative phenotype. This suggests that methylation has a role in 
regulating a portion of the genes differentially expressed between the proliferative and invasive 
phenotype. We hypothesized that the 73 genes with both differential DNA methylation and 
mRNA expression between the proliferative and invasive melanoma cells were likely to be true 
targets of epigenetic regulation in melanoma. To determine which groups of genes were 
functionally important, we performed pathway analysis of the 73 genes on MetaCore. We looked 
for enrichment of pathways under GO processes, process networks and Pathway maps 
(Supplemental Table 2). Interestingly, we observed significant enrichment in pathways involved 
in EMT, melanoma and cell differentiation. We decided to focus on SOX9 for validation due to 
its known function in melanocyte differentiation and melanoma progression [29, 33, 34]. 
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Figure 1. Phenotype specific expression of DNMTs and DNA methylation patterns. (a) Western blot 
for DNMT1 and DNMT3a and DNMT3b on five proliferative phenotype and five invasive phenotype cell 
lysates. GAPDH was used as a loading control. Optical density of each band was measured and 
normalized to GAPDH intensity. (b) Global methylation analysis by ELISA for methyl-cytosine on five 
proliferative cell cultures and five invasive cell cultures. There was a significant difference (p < 0.05, 
Student’s t-test) in global methylation between the proliferative and invasive phenotype melanoma cells. 
(c) Heat map representing the 406 gene promoters differentially methylated between the proliferative and 
invasive phenotype cultures. (d) Heat map representing the top 250 genes differentially expressed 
between the proliferative and invasive phenotype. 
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Sox9 expression is silenced in proliferative melanoma cells through promoter DNA-
methylation 
From the methylation array, the area that had the most enrichment for methylation was about 
2kb upstream of the SOX9 promoter, thus we validated the CpG island located there via 
sequencing of bisulfite-treated genomic DNA in the 10 melanoma cell cultures (Figure 2A). 
There are three predicted transcription factor binding sites in that upstream promoter region of 
SOX9 for MEF2, E2F and HNF3B. We analyzed the DNA methylation status of a cluster of 17 
CpGs across a 283-bp region and 15 CpGs across a 256-bp region of a CpG island, located 
approximately −2500 bp to −2000 bp upstream of the SOX9 transcriptional start site. The 
majority of CpGs in both regions of the SOX9 promoter were consistently methylated in the 
proliferative phenotype melanoma cell cultures and consistently unmethylated in the invasive 
phenotype melanoma cell cultures.  
 
To confirm that promoter DNA hypermethylation correlated with transcriptional silencing of 
SOX9, we assessed mRNA levels using real-time RT-PCR in the ten melanoma cell cultures. 
SOX9 mRNA was expressed robustly in the invasive phenotype melanoma cell cultures 
compared to the proliferative phenotype melanoma cell cultures (p < 0.05) (Figure 2B). Protein 
expression of SOX9 was detected in all invasive phenotype melanoma cell lysates, but little to 
no expression of SOX9 was seen in the proliferative phenotype melanoma cell lysates (Figure 
2C).  To validate that SOX9 is indeed regulated by DNA methylation, we treated the five 
proliferative phenotype melanoma cell cultures with 5 µM 5-Aza-2’-deoxycytidine (a DNMT 
inhibitor) for 72 hours. Reexpression of SOX9 was detected by western blot (Figure 2D).  Thus, 
SOX9 expression is regulated by DNA methylation between the proliferative and invasive 
phenotype.   
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Figure 2. Validation of SOX9 methylation. (a) Lollipop diagrams of bisulphite sequencing of SOX9 
promoter. Black lollipops are methylated CpGs; white lollipops are unmethylated CpGs. A minimum of 5 
clones were sequenced for each cell culture. (b) mRNA expression of SOX9 normalized to the 
housekeeping gene RPL28 across ten melanoma cell cultures. Results are presented as mean +/- s.d., 
n=3. Statistical significance of differential expression between the proliferative and invasive phenotype 
cell cultures was determined by Student’s t-test. (c) Western blot for SOX9 in ten melanoma cell cultures. 
GAPDH served as loading control. (d) Western blot for SOX9 of five proliferative melanoma cell cultures 
treated with 5-aza-2-deoxycytidine (Aza) 
 
SOX9 mediates proliferation and invasion in melanoma cell cultures 
SOX9 is expressed in the invasive phenotype and we have previously described the greater 
invasive potential of invasive versus proliferative phenotype melanoma cells [30, 35]. We 
hypothesized that some of the differentially expressed genes could have a role in generating 
this invasive capacity, thus we wanted to see if SOX9 would have a role in invasion. SOX9 was 
knocked down with siRNA, and then the invasive ability of two invasive phenotype melanoma 
cell cultures was measured: M080201 and M080310. Treatment with two independent siRNAs 
for SOX9 achieved about 70% knockdown of SOX9 mRNA in M080201 and M080310 (Figure 
3A). The invasive capacity of M080201 and M080310 decreased significantly (p < 0.05) from 
30% to 11.5% and from 64.8% to 36.6% respectively after 48 hours treatment with siRNA 
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targeting SOX9 (Figure 3B, C). Proliferation was unaltered from SOX9 knockdown (data not 
shown). 
 
Consistent with this observation, we overexpressed SOX9 in proliferative phenotype melanoma 
cell cultures (i.e. M010817 and M980513) by lentiviral transfection (Figure 3D). Overexpression 
of SOX9 was previously shown to drive melanoma cells into cell cycle arrest [29]. We measured 
proliferation and cell cycle progression by EdU and PI staining respectively and observed the 
cells transfected with vector have 50.5% in G1 phase, 37% in S phase, and 12.5% in G2/M 
phase, whereas the cells overexpressing SOX9 have 64.8% in G1 phase, 17.7% in S phase, 
and 17.5% in G2/M phase (p<0.05) (Figure 3E, F). The invasive capacity of M010817 and 
M980513 were significantly increased from 0.95% to 9.0% (p<0.05) and from 0.67% to 4.8% 
(p<0.05) from SOX9 overexpression (Figure 3G, H). In concordance with previously published 
data on SOX9 in melanoma, we also see G1/G0 arrest when SOX9 is overexpressed along with 
increased invasion. 
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Figure 3. SOX9 mediates invasion and cell cycle arrest. (a) SOX9 knockdown by siRNA in two 
melanoma cell cultures M080201 and M080310. (b) Boyden chamber assay for siSOX9 knockdown in 
M080201 and M080310. (c) Representative picture of the Boyden chamber assay for knockdown of 
SOX9 in M080310. Top panel shows M080310 cells treated with control siRNA (siCtrl). Bottom panel 
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shows M080310 cells treated with siSOX9_1. (d) SOX9 overexpression by lentiviral expression in 
proliferative phenotype melanoma cell cultures M010817 and M980513. (e) Proliferation assay by EdU 
pulse in cell cultures transfected with empty vector and pLenti-SOX9. (f) Cell cycle analysis by PI staining 
for cell cultures transfected with empty vector and pLenti-SOX9 (top and bottom left panels). Quantitation 
of cell cycle analysis (* = p < 0.05, right panel). (g) Boyden chamber assay for SOX9 overexpressing 
melanoma cell cultures M010817 and M980513 (* = p < 0.05). (h) Representative picture of the Boyden 
chamber assay for SOX9 overexpression in M010817. Top panel shows M010817 transfected with empty 
vector. Bottom panel shows M010817 transfected with SOX9.  
 
SOX9 induces a partial invasive phenotype in proliferative melanoma cells 
To determine the effect of SOX9 overexpression on the proliferative phenotype, we performed 
microarray analysis of M010817 cells overexpressing SOX9. We detected 643 genes down 
regulated at least 2 fold and 450 genes up regulated at least 2 fold (p < 0.05 (Figure 4A, 
Supplemental Table 3). We overlapped the gene signature from the SOX9 overexpression 
microarray with the gene signature from the 10 melanoma cell culture microarray to ask if SOX9 
induced genes are enriched in the invasive phenotype. There were 98 genes that were up-
regulated and 55 genes that were down-regulated in both the SOX9 overexpression and 
invasive phenotype gene sets. Hypergeometric distribution of the overlap of the SOX9 
microarray with 10 melanoma cell culture array was significant (p < 0.001) (Figure 4B). Thus, 
SOX9 apparently regulates about 10% of the genes that define the invasive phenotype gene 
set. This suggests that SOX9 activation contributes to the invasive phenotype but other factors 
are also required for the full transition.  
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Figure 4. SOX9 microarray (a) Heat map of M010817 cells overexpressing SOX9.  (b) Overlap of up-
regulated genes and down-regulated genes between the SOX9 microarray and 10 melanoma cell culture 
microarray.  
 
In vivo function of SOX9 overexpression 
To examine the effects of SOX9 in vivo, we utilized the B16F1 mouse melanoma cells which do 
not express sox9 and are known not to metastasis in a tail vein injection assay. We transfected 
murine sox9 transiently into the B16F1 cells and monitored its expression over 288 hours. 
Expression of sox9 decreases over time but protein is still detectable at 288 hours (Figure 5A). 
To assess the in vivo metastatic potential of sox9, C57BL/6J mice were intravenously injected 
with B16F1 cells transfected with sox9 and empty vector (Figure 5B). 12 days after injection, the 
mice were sacrificed and the lungs were analyzed for tumor nodules. B16F1 cells expressing 
sox9 had significantly more metastases compared to control, p < 0.05.   
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Figure 5. In vivo function of sox9 overexpression. (a) Western blot analysis of transient sox9 
overexpression in B16F1 up to 12 days. (b) Representative pictures of B16F1 cells intravenously injected 
into C57BL/6J mice 12 days after injection (n = 5 mice per group). Quantification (right graph). * = p < 
0.05 Mann-Whitney U test. 
 
Validation with TCGA melanoma dataset 
The Cancer Genome Atlas (TCGA) has a melanoma dataset available for public access which 
contains over 300 tissue samples with RNAseq, DNA methylation and clinical data. To validate 
our claim that SOX9 is regulated by DNA methylation, we performed a correlation analysis of 
SOX9 expression to SOX9 promoter methylation using the data from the TCGA database. 
Three consecutive probes cg10471574, cg21049501, and cg06234051 in the SOX9 promoter 
region have an anti-correlative association with the expression of SOX9, r= -0.58, -0.61, and -
0.71 respectively (Figure 6A). Since high DNA methylation of SOX9 is correlated with low SOX9 
expression it provides strong evidence that DNA methylation regulates SOX9 expression in 
vivo.  
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The melanoma dataset contains 68 primary samples and 268 metastatic samples. The 268 
metastatic samples are comprised with 172 lymph node tumors, 59 regional cutaneous or 
subcutaneous metastases and 37 distant metastases. Due to the diversity of this dataset we 
analyzed the primary and metastatic samples individually. We segregated the population into 
thirds by SOX9 expression. We compared the upper and lower thirds for our analysis labelling 
them SOX9 high and SOX9 low. In both primary and metastatic datasets, the SOX9 high group 
had at least 3 times more expression than the SOX9 low group. We interrogated clinically 
relevant factors such as TNM staging, age, gender, and tumor type between the SOX9 high and 
SOX9 low group in the primary and metastatic datasets (Table 1, Supplemental Table 4). All 
parameters were statistically insignificant as tested by the Chi-squared test and t-test for age in 
the primary melanoma dataset. Only two clinical parameters were significant in the metastatic 
dataset. T1 was significant 2 vs 11 (p = 0.013) in the SOX9 low versus SOX9 high respectively. 
N0 was also significant 26 vs 44 (p = 0.031) in the SOX9 low versus SOX9 high respectively. 
 
Table 1 – Clinical charactistics of TCGA melanoma SOX9 population  
Clinical Parameter SOX9 low SOX9 
high 
p value  
T0 15 13 0.706  
T1 2 11 0.013 * 
T2 17 17 1  
T3 20 13 0.223  
T4 16 16 1  
N0 26 44 0.031 * 
N1 16 9 0.162  
N2 15 9 0.221  
N3 12 9 0.513  
NX 1 0 1  
M0 67 64 0.793  
M1 2 6 0.157  
Female 29 25 0.586  
Male 45 49 0.68  
Lymph Node 48 49 0.919  
Regional Cutaneous or Subcutaneous Metastasis 17 14 0.59  
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Distant Metastasis 9 11 0.655  
Age 57 59.9 0.213a   
     
a: Student's t-test     
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Figure 6. Validation of SOX9  methylation in TCGA and correlation with clinical features. (a) 
Correlation plots of RNAseq reads to B-values of methylation for SOX9. Three methylation probes of 
SOX9 are shown here to have significant anti-correlation of gene expression and DNA methylation. (b) 
Heatmap of the 427 genes differentially expressed between the SOX9 high and SOX9 low metastatic 
melanoma samples. 
 
We next tested if the genes differentially expressed between the SOX9 high and SOX9 low 
patients in the primary and metastatic datasets were the same in our SOX9 overexpression 
microarray. A total of 21 genes were differentially expressed between the SOX9 high and SOX9 
low groups in the primary dataset with a minimum fold change of 2 and FDR corrected p-value < 
0.05 (Supplemental Table 5). No genes from this set overlapped with the SOX9 microarray. A 
total of 427 genes were differentially expressed between the SOX9 high and SOX9 low groups 
in the metastatic dataset with a minimum fold change of 2 and FDR corrected p-value < 0.05 
(Figure 6B, Supplemental Table 6). A total of 31 genes overlapped with the SOX9 microarray. 
Although the overlap was small, hypergeometric distribution of this overlap was significant (p < 
0.05). To examine the pathways in which, SOX9 might play a role in vivo, we performed 
pathway analysis on the 427 genes. We saw significant enrichment of many EMT pathway 
processes such as “Regulation of epithelial-to-mesenchymal transition (EMT)”, “TGF-beta 
dependent induction of EMT via SMADs”, and “Melanocyte development and pigmentation” 
(Figure 7A).  
 
We interrogated if SOX9 has a role in overall patient survival in all patients regardless of primary 
or metastatic disease. There was a significant difference in 10 year survival rates between the 
SOX9 high and SOX9 low groups. SOX9 high patients had a median survival rate of 3.9 years 
whereas the SOX9 low patients had a median survival time of 5.8 years (p < 0.05) (Figure 7B). 
Cox multivariate analysis was carried out to identify if age, gender, TNM stage, and tumor type 
were significant contributing factors for 10 year survival of SOX9 high and SOX9 low patients. 
SOX9 expression (Hazard ratio 2.343; 95% Confidence interval 1.402 – 3.915; p = 0.001; SOX9 
high vs SOX9 low) and T4 stage (Hazard ratio 2.145; 95% Confidence interval 1.01-4.557; p = 
0.047; T4 vs T0) were significant (Table 2).We also segregated the patients into primary, lymph 
node metastasis and regional/distant metastasis and reassessed survival based on SOX9 
expression. We saw that SOX9 expression in primary tumors had no effect on patient survival. 
However, the cohort of patients with high SOX9 expression in lymph nodes had significantly 
lower survival (p = 0.03), as in the regional/distant metastasis cohort (p = 0.01) (Figure 7C). 
 
Table 2 – Multivariate Cox Regression 
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Covariate HR Lower 95% Upper 95% p-value  
SOX9 (SOX9 low = 0, SOX9 high =1) 2.343 1.402 3.915 0.001 *** 
Age 0.995 0.977 1.103 0.59  
Gender (female = 0, male =1) 0.756 0.457 1.25 0.276  
T0 (used as reference)      
T1 0.431 0.117 1.598 0.208  
T2 0.943 0.416 2.138 0.888  
T3 1.022 0.489 2.132 0.955  
T4 2.145 1.01 4.557 0.047 * 
N0 (used as reference)      
N1 1.673 0.813 3.446 0.162  
N2 1.365 0.673 2.771 0.388  
N3 1.322 0.574 3.044 0.512  
M0 (used as reference)      
M1 2.023 0.672 6.09 0.21  
Lymph Node (used as reference)      
Regional Cutaneous or Subcutaneous Metastasis 0.844 0.452 1.577 0.595  
Distant Metastasis 1.83 0.957 3.499 0.068  
 
We tested all 31 overlapping genes for survival benefit in the metastatic dataset (Supplemental 
Table 7). 12 of the genes of this set were up-regulated and 19 were down-regulated when 
SOX9 expression was high. Most of the genes, 92% (11/12), that were up-regulated when 
SOX9 expression is high had no influence on patient survival, only 1 gene 7% (1/12) was 
associated with improved survival (Figure 7D). This suggests that the genes up-regulated by 
SOX9 are not direct factors for patient survival. Interestingly, 58% (11/19) of the genes down-
regulated when SOX9 expression is high were associated with improved survival and the other 
42% (8/19) had no influence on patient survival (Figure 7D).  This suggests that SOX9 
represses a group of genes important for patient survival. Taken together, high SOX9 
expression leads to poor survival possibly due to the down-regulation of several genes that 
influence patient survival. 
 
SOX9 binds to the promoter regions of its target genes 
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Using the SOX9 binding motif to screen for potential binding sites on the promoter regions from 
the 31 overlapping targets of the SOX9 microarray and the TCGA melanoma dataset, we found 
19 of the 31 genes had a potential SOX9 binding site within a 3kb region upstream from the 
TSS. To determine whether SOX9 directly binds to the promoter regions of these genes, we 
performed ChIP analysis using SOX9 antibodies on M010817-SOX9 cells and measured SOX9 
occupancy at promoter regions of TMEM158, TBX3 and FYB, for which we could design 
specific primers for qPCR (Figure 7E). The specificity of this assay was demonstrated by the 
enrichment of three known SOX9 target sequences, COL2A1 intron 1 [36], p21 [29] and SOX10 
(Shahkova et al. submitted), as compared to a non-target gene (IP10). We observed a specific 
association of SOX9 with TMEM158, TBX3 and FYB, suggesting that TMEM158, TBX3 and 
FYB are direct targets of SOX9 in melanoma. 
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Figure 7. TCGA analysis of SOX9. (a) Pathway analysis from MetaCore for SOX9 reveals many 
pathways involved in EMT. (b) Median survival time for patients with high SOX9 expression is 3.9 years 
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(n=74). Median survival time for patients with low SOX9 expression is 5.8 years (n=74). The difference in 
survival is significant (p < 0.05). (c) Survival analysis for high and low SOX9 expression segregated into 
primary, lymph node and metastatic cohorts. (d) Pie charts displaying the number of SOX9 target genes 
that have a contribution to patient survival. (e) ChIP analysis for SOX9 binding targets. Enrichment of the 
promoter regions for TMEM158, TBX3, and FYB were similar to positive controls COL2A1, p21 and 
SOX10 and greater than negative control IP10. Data are shown as bound vs input. Error bars indicate 
standard error of the mean of 3 independent experiments. IgG controls not shown on graph because they 
were below detection limit. 
 
Conclusion 
Phenotypic, genetic, and epigenetic heterogeneity is a common feature in human melanomas 
[4, 5, 14, 37]. Tumor subpopulations can be transient and have been seen to switch between 
phenotypic states in vivo [4, 6, 9, 12, 38]. We have previously described two subpopulations in 
melanoma, the proliferative phenotype and the invasive phenotype, which are defined by 
specific gene signatures, in vitro characteristics and response to drug treatment [11, 13, 30, 35, 
39]. Briefly, proliferative phenotype melanoma cells are distinguished by a high proliferative 
capacity and low invasive capacity and the invasive phenotype melanoma cells are 
distinguished by a low proliferative capacity and high invasive capacity. In this study, we found 
specific DNA methylation signatures for the proliferative and invasive melanoma phenotypes. 
We observed the invasive phenotype melanoma cell cultures had modest decrease of 5% in 
global methylation compared to the proliferative phenotype melanoma cell cultures. This may be 
due to decreased DNMT1 protein expression in the invasive phenotype melanoma cells. Global 
methylation levels have been observed to decrease as a cancerous lesion progresses from a 
benign tumor to metastasis [22, 40], and we observed our invasive phenotype melanoma cell 
cultures had decreased DNA methylation levels and were more invasive than the proliferative 
phenotype melanoma cell cultures, suggesting the invasive cell cultures have progressed 
further in malignancy. Differential expression of the de novo DNA methyltransferase DNMT3b 
was also seen between the proliferative and invasive phenotype. These data are consistent with 
a model in which DNMT1 and DNMT3b have phenotype specificity and contribute to 
transcriptional heterogeneity by altering the methylation landscape of a melanoma cell in the 
context of melanoma phenotype switching.  Pathway analysis of the 73 gene signature from the 
DNA methylation and gene expression array lead to the discovery of many transcription 
networks involved in development. These transcription factors were found to be hypomethylated 
and highly expressed in the invasive phenotype, which would suggest the invasive melanoma 
cell cultures may revert to a dedifferentiated state.  
 
95 
 
A number of other studies that have looked at genome-wide DNA methylation in melanoma 
have indicated that several tumor suppressors are silenced by DNA methylation compared to 
normal melanocytes [41-43] and compared to benign nevi [44]. Also, a recent study 
investigating 5-hydroxymethylation (5-hmC) in melanoma found a global decrease of 5-hmC 
was necessary for melanoma formation [45]. The results from these studies indicate aberrant 
DNA methylation is an important process in melanoma development and progression. In our 
work, we looked at the differences in DNA methylation landscape between ten primary 
melanoma cell cultures and uncovered two distinct populations, as previously demonstrated by 
gene expression microarray analysis from our group [13]. Surprisingly, the targets we found to 
be differentially methylated between the two phenotypes do not overlap with the targets found to 
be differentially methylated between normal melanocytes and melanoma, and benign nevi and 
melanoma. We did not detect any differential methylation in validated methylation gene sets 
such as COL1A2, NPM2, HSPB6, DDIT4L, and MTIG from Koga et al. [42] or UCHL1, COL1A2, 
THBS1, and TNFRSF10D from Bonazzi et al. [41]. As those studies were comparing the 
methylation state of normal melanocytes to melanoma and in this study we compare within 
melanoma phenotypes, this might indicate that a different set of pathways are activated or 
silenced by DNA methylation in melanoma progression compared to melanoma initiation. In 
either case, it is clear that epigenetic modifications such as DNA methylation play an important 
role in melanoma initiation as well as progression, and embryonic developmental program 
reactivation may be one of the critical outcomes of this modulatory activity.    
 
In our study, a subset of our melanoma cell cultures had lower SOX9 expression due to a 
hypermethylated promoter and the other subset with high SOX9 expression had a 
hypomethylated promoter. We confirmed that SOX9 is regulated by DNA methylation by treating 
low SOX9 expressing cells with 5-aza-2-deoxycytidine treatment and saw reexpression of 
SOX9. To determine if the regulation of SOX9 by DNA methylation is a common mechanism in 
melanoma or just seen within our melanoma cell cultures, we interrogated the melanoma TCGA 
dataset for SOX9 and found that SOX9 gene expression and DNA methylation are anti-
correlated at three consecutive methylation probes in 293 samples. This provides strong 
evidence that specific DNA methylation is the molecular mechanism that regulates SOX9 
expression in melanoma. Alcazar et al. demonstrated that after Decitabine treatment of A375 
and B16 melanoma cells, the promoter of SOX9 becomes hypomethylated and SOX9 is re-
expressed with induction of p27 and p21 for cell cycle arrest [27]. Passeron et al. also observed 
that SOX9 was down-regulated in some melanoma cell lines and induction of SOX9 expression 
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in these melanoma cell lines resulted in lower proliferation due to upregulation of p21 [29].  We 
also overexpressed SOX9 in low SOX9 melanoma cell cultures and observed G1/S cell arrest, 
which is consistent with the study from Passeron et al. Although the proliferation rate is reduced, 
the invasive capacity of these SOX9 overexpressing cells is increased, which phenocopies the 
endogenous SOX9 expressing cells. Conversely, knockdown of SOX9 in the invasive 
phenotype melanoma cells reduced the invasive capacity of the cells. Microarray analysis of 
SOX9 overexpression revealed an EMT-like transcriptional signature and had 10% overlap with 
invasive phenotype gene signature which supports the notion that SOX9 is a factor that 
contributes to the invasive phenotype. In vivo, sox9 expression in B16F1 cells increases their 
metastatic potential causing more tumor lung nodules in the tail vein injection assay. Taken 
together, SOX9 is a gene that is regulated by DNA methylation and functionally, SOX9 mediates 
cell cycle progression, invasion and metastasis in melanoma. 
 
The Cancer Genome Atlas (TCGA) is a great resource for clinical and next-generation 
sequencing data on human tumors. We took advantage of the melanoma dataset and 
demonstrated that SOX9 expression levels have a significant impact on survival of metastatic 
melanoma patients but SOX9 did not have a significant impact on survival in patients with 
primary melanomas. This could suggest that SOX9 is required for progression of primary 
melanoma into metastasis and metastatic tumors with high SOX9 are more aggressive to the 
patient. There were no clinical metrics that could distinguish SOX9 high or low in primary 
melanoma. Only T1 and N0 stage in metastatic melanomas were significant between SOX9 
high and low. Survival analysis of metastatic patients with high SOX9 expression versus low 
SOX9 expression revealed a significant difference in the overall 10 year survival rates. Patients 
with high-SOX9 expressing tumors had a 2.3 times increased risk of death compared to patients 
with low SOX9 expressing tumors. Based on these findings and the invasive properties of high 
SOX9 expressing melanomas, it would suggest that SOX9 expression in melanomas could 
push the tumor toward more aggressive metastasis. Thus, SOX9 could potentially be a 
prognostic marker for metastatic melanoma.  
 
We performed differential gene expression analysis on the RNAseq dataset where we defined 
the SOX9 high group as having a minimum of 3 fold greater expression than the SOX9 low 
group. We only saw an overlap of 31 genes between both datasets however the overlap was 
significant as determined by hypergeometric distribution. The contribution of heterogeneity in 
the melanoma TCGA patient population would be one of largest factors for the difference in 
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gene signatures between our SOX9 microarray and TCGA RNAseq data. Nonetheless, the 
significant overlap of genes narrow down the potential targets of SOX9. To confirm that the 
targets of SOX9 have prognostic value for the patients, we performed survival analysis on all 31 
genes. Surprisingly, 58% (11/19) of the genes down-regulated by SOX9 were associated with 
improved survival, which strongly suggests SOX9 represses a set of genes that decrease tumor 
malignancy. Genes that were up-regulated by SOX9 expression had little impact on patient 
survival which implies that SOX9 expression alone is sufficient to drive disease progression. 
From this list of 31 genes, 19 of them had a potential SOX9 binding site in its promoter. We 
could validate TMEM158, TBX3 and FYB as direct targets of SOX9 binding by chromatin 
immunoprecipitation. FYB is downregulated when SOX9 levels are high suggesting a repressive 
effect of SOX9 on this gene. FYB is required for inflammatory cytokine production [46] but no 
known link has been established with melanoma. TMEM158 is upregulated by SOX9 but no 
clear role has been established for the gene in melanoma. TBX3 is also upregulated by SOX9 
and TBX3 is known to cause increased invasiveness in melanoma [47, 48], suggesting TBX3 
could be an effector gene that drives the invasive phenotype we see in SOX9 high cells and in 
patients.   
 
In conclusion, we found SOX9 to be regulated by DNA methylation, and high SOX9 expression 
leads to poor survival in melanoma patients due to the activation of EMT-like genes and the 
down regulation of potential tumor suppressor genes in melanoma cells. This was confirmed in 
vivo, and new direct targets of SOX9 that may mediate its function in tumor progression were 
identified by transcriptional profiling and chromatin-immunoprecipitation. Future therapies 
targeting SOX9 could be beneficial for patients to prevent progression and especially when 
combined with therapies targeting cells of the proliferative phenotype. Further investigation 
would be required to determine if SOX9 would have early prognostic value for tumor 
malignancy.    
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genomic data. Finally, all research on human materials was done according to Swiss law and 
following the Declaration of Helsinki on medical research. Consenting patients contributed 
surplus melanoma biopsy material according to IRB approval numbers (Ek.647/800), and cell 
lines were generated following IRB KEK-ZH-Nr.2014-0425). 
 
Materials & Methods 
Cell culture. Melanoma cell cultures were established from surplus material from primary 
cutaneous melanoma and melanoma metastases removed by surgery [49]. Written informed 
consent was approved by the local IRB (EK647 and EK800). Clinical diagnosis was confirmed 
by histology and immunohistochemistry. Melanoma cells were released from tissue biopsies 
and grown as previously described [50]. Melanoma cell cultures were maintained in RPMI 
(Invitrogen, Carlsbad, CA, USA) supplemented with 5 mM glutamine, 1 mM sodium pyruvate 
and 10% heat-inactivated fetal calf serum, and cultured at 37°C and 5% CO2. As RNA was 
extract previously from these cell cultures for gene expression array analysis, all cell cultures 
used for experiments in this paper were within 5 passages of the RNA isolation time point.  
 
5-methylcytosine relative content analyses. Global DNA methylation level was evaluated by 
MethylFlash Methylated DNA Quantification Kit (Epigentek, Farmingdale, NY, USA) as per 
manufacturer’s instructions.  
 
MeDIP assay and analysis. The MeDIP assay was performed as described [31]. A monoclonal 
antibody to 5-Methylcytidine (BI-MECY-100, Eurogentec, Belgium) was used for 
immunoprecipitation. The immunoprecipated DNA and sonicated input DNA were differentially 
labeled with fluorescent dyes (Cy3 and Cy5, respectively) and hybridized to Human DNA 
Methylation 3x720K CpG Island Plus RefSeq Promoter Arrays (Roche Nimblegen, Madison, WI, 
USA). Acquisition and analysis was performed using Nimblescan 2.5 and R package DMR 
provided by Nimblegen. All data has been deposited into NCBI GEO GSE57971.  
 
Gene expression analysis. Gene expression datasets were obtained from NCBI GEO 
GSE33728 [13], and analysis was performed by R using the limma package. P-values were 
adjusted by FDR multiple hypothesis test correction.  
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Bisulphite sequencing. Genomic DNA was extracted from primary melanoma cell cultures and 
subjected to bisulfite (BS) modification (EZ DNA Methylation Gold Kit, Zymo Research, Irvine, 
CA, USA). Primers used for bisulphite PCR are described below.  To validate the DNA 
methylation status of individual DNA molecules, we cloned bisulfite-converted PCR fragments 
into the pCR2.1 vector using the TOPO-TA cloning kit (Invitrogen, Carlsbad, CA, USA). 
Individual colonies were screened for the insert, and the region of interest was sequenced using 
M13 primers. A minimum of 5 clones were sequenced for each region of interest. Lollipop 
diagrams were generated using BiQ Analyzer [51]. 
 
Primers for bisulphite sequencing  
Gene Primer Tm 
SOX9_1 F: 5'-GGATTGGGGTTTTTTATTTTT-3' 59ºC 
 R: 5'-TTCAATTTTCTTCCCTTTCCT-3'  
SOX9_2 F: 5'-AGGTTATTAGGGTAGATTGGAGG-3' 59ºC 
 R: 5'5AAATACATATCCCATCACAACC-3'  
 
 
Treatment with Decitabine. Decitabine (5-Aza-2′-deoxycytidine, Sigma Chemical [Aza]) was 
dissolved in DMSO as a 10 mM stock solution, aliquoted and kept at −20°C. Primary melanoma 
cell cultures were seeded in Petri dishes (∼5000 cells/cm2) in RPMI untreated or treated with 
Aza (5 μM) for 72 hours, with fresh drug-supplemented medium every 24 hours. 
 
mRNA expression analysis. Total RNA was isolated using Trizol according to manufacturer’s 
instructions (Invitrogen). 1 μg aliquots of RNA were reverse transcribed with Reverse 
Transcription System (Promega) according to the manufacturer's instructions. Data collection 
and analysis were performed by ABI Viia7 Fast Real-Time PCR Systems (Applied Biosystems). 
Gene expression values of averaged triplicate reactions were normalized to RPL28 expression 
levels. RPL28 primers are as follows: 5’-GCAATTGGTTCCGCTACAAC-3’ and 5’-
TGTTCTTGCGGATCATGTGT-3’.The primers for RT-PCR were purchased from QIAGEN: 
SOX9 (Hs_SOX9_1_SG) 
 
Western Blot. Cells were washed twice with cold phosphate-buffered saline (PBS) and lysed at 
4ºC in lysis buffer containing 20 mM Tris–HCl (pH 7.5), 1% Triton X-100 (Sigma-Aldrich, St 
Louis, MO, USA), 137 mM NaCl, 10% glycerol, and protease and phosphatase inhibitors 
(Roche, Basel, Switzerland). Proteins were separated by SDS-PAGE using the NuPAGE SDS-
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PAGE Gel System (Invitrogen) under reducing conditions. 15 μg of protein was mixed with 9 μl 
of NuPage LDS sample buffer (4x) (Invitrogen, NP0007), 3.6 μl of NUPAGE 
Sample Reducing (Invitrogen, NP0009) and filled up to 36 μl with RIPA buffer. This mixture was 
incubated at 85°C for 10 minutes while shaking at 900 rpm. Samples were loaded on NuPage 
precast gels (Invitrogen). Membranes were probed with the following antibodies: SOX9 
(GTX109661, GeneTex, Hsinchu City, Taiwan); DNMT1 (ab13537, Abcam, Cambridge, UK); 
DNMT3a (ab2850, Abcam, Cambridge, UK); DNMT3b (ab16049, Abcam, Cambridge, UK); 
GAPDH (ab9483, Abcam, Cambridge, UK);  
 
siRNA knockdown. Silencing RNA (siRNA) transfection of melanoma cells was carried out 
using INTERFERin transfection solution according to the manufacturer’s protocol (Polyplus-
transfection, Illkirch, France). Cells were transfected with 5 nM of siRNA (Qiagen) for 72 hours 
before RNA or protein was extracted. As control siRNA, the All-Star negative siRNA sequence 
(Qiagen) was used, and gene-specific siRNAs targeting siSOX9 (SI00007595, SI00007609) 
were obtained from Qiagen. 
 
SOX9 lentiviral transfection 
Lentiviral particles containing plasmids expressing full-length SOX9 cDNA or eGFP were 
transfected into melanoma cells for 48 hours. Media supplemented with 4 ng/mL blasticidin was 
used for selection. After 1 week of selection, protein lysate was extracted and analyzed for 
SOX9 expression. Plasmids for eGFP and SOX9 were a kind gift from Dr. Thierry Passeron 
[29]. 
 
SOX9 transient transfection 
Empty vector or vector containing murine sox9 (a kind gift from Prof. Lukas Sommer) was 
transfected into B16F1 cells with jetPEI (Polyplus, France) according to manufacturer’s protocol. 
Protein was isolated at 24 hours, 72 hours, 144 hours and 288 hours after transfection and 
analyzed for sox9 expression by western blot.  
 
Microarray and pathway analysis 
Gene expression of eGFP and SOX9 transfected cells were analyzed using the Affymetrix 
Human Genome U133 Plus 2.0 Array at the Functional Genomics Center Zurich (FGCZ). 
Differential gene expression was determined by R package limma [52]. Pathway analysis was 
performed using MetaCore (GeneGo Inc, New York, USA).  
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 Proliferation and Cell cycle analysis 
For cell cycle analysis, the Click-iT EdU Alexa Fluor 647 Flow Cytometry Assay Kit (Invitrogen) 
was used. Cells were labelled with PI according to the manufacturer’s protocol and the DNA 
content was measured using a BD FACSCanto II flow cytometer (BD Biosciences) and BD 
FACSDiva software (BD Biosciences). Cell cycle analysis was performed in triplicate. 
  
Boyden chamber invasion assay. Cells were seeded on FluoroBlok 24-multiwell Insert 
System (351157, BD Biosciences) and Biocoat Tumor Invasion System (354165, BD 
Biosciences). The invasion assay was performed as per manufacturer’s instructions. Migrated 
and invaded cells were labeled with Calcein AM fluorescent dye (354216, BD Biosciences) and 
fluorescence was measured with Tecan GENios (Tecan, Männendorf, Switzerland) using 485 
nm excitation and 535 nm emission. Relative invasion was calculated as the ratio of the 
fluorescence of invading cells of the Biocoat Tumor Invasion System divided by the 
fluorescence of migrating cells of the FluoroBlok 24-multiwell Insert System. Boyden chamber 
assays were performed in triplicate. 
 
Viability assay 
Cells were seeded in 24-well microplates at a density of 2 × 104 cells, and cell growth was 
determined with a standard colorimetric assay measuring 3-(4,5-dimethylthiazol-2-yl)-2,5 
diphenyltetrazolium bromide (MTT) (Sigma-Aldrich, St Louis, MO, USA) reactivity after 72 
hours. MTT assays were performed in triplicate. 
 
Chromatin Immunoprecipitation 
ChIP analysis was performed as previously described [53]. The Sox9 antibody was from Santa 
Cruz Biotechnology (sc-20095, Santa Cruz Biotechnology). Primer sequences were designed 
around SOX9 binding motifs [54, 55] from the transcription start site (TSS) to 3 KB upstream of 
the TSS. Primers for p21, COL2A1, TMEM158, TBX3, FYB, SOX10 and IP10 are as follows: 
COL2A1-F ATCCTCCTTTGTGAGGCTTGTT 
COL2A1-R AGTACGAGAGAACCCACTGGAC 
p21-F TGATGTGCCACAGTTCACAA 
p21-R TCCTGCCAGTTTTCCTGTTC 
TMEM158-F TCTGCTGTGTTGGAGCCATT 
TMEM158-R GTCTCGCCTTAGTGCTACCG 
TBX3-F CTCGCCCCTTTCTTTCCCTT 
TBX3-R GGGGGTGTTATGAGCCAACA 
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FYB-F CTCACATTGCATGGGGACG 
FYB-R ATGGGCTTATCACCGGAAGG 
SOX10-F CCTCTGCCTCGTGTGACTAC 
SOX10-R TCCTGTCTGGAGTGGGCTG- 
IP10-F GGGAAATTCCGTAACTTGGA 
IP10-R AAGCCATTTTCCCTCCCTAA 
 
In vivo metastasis 
B16F1 cells were transfected with empty vector or vector containing murine sox9. 2 x 105 cells 
were injected intravenously into C57BL/6J mice, 5 mice per group (Harlan Laboratories). After 
12 days mice were sacrificed and lungs were examined for metastasis. Statistics were 
performed using the Mann-Whitney U test. All animal experiments have been approved by the 
veterinary authorities of Canton of Zurich, Switzerland, and were performed in accordance with 
Swiss law. 
 
TCGA analysis 
The SKCM DNA methylation, RNA-seq and clinical dataset were downloaded on July 28, 2014 
for analysis (http://cancergenome.nih.gov/). Normalized reads from the level 3 RNA-seq data 
was used for analysis. The dataset was segregated into primary tumors and metastatic tumors 
for analysis. Chi-squared test was performed on the clinical parameters between the SOX9 high 
and low groups. Differential expression was analyzed with voom from the limma package [52]. 
Log rank test and Cox proportional hazard ratio were analyzed by the survival R package [56]. 
DNA methylation β-values were calculated by minfi [57]. Correlation was calculated by 
Spearman’s rank correlation coefficient. 
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Supporting Information 
 
Supplemental Figure 1. MLANA expression between the proliferative and invasion phenotype. MLANA 
expression is a marker for the proliferative phenotype. Ten melanoma cell cultures were divided into the 
proliferative and invasive phenotype by MLANA. GAPDH was used as the housekeeping gene. 
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8. Discussion 
Melanoma is a highly heterogeneous disease as seen by the multiple unique clinical 
presentations, the multiple genetic aberrations it can harbor, and the plasticity in behavior 
demonstrated by phenotype switching. Intratumoral heterogeneity and intrapatient heterogeneity 
have created a multitude of challenges for therapies that could be applied to all melanoma 
patients (1, 2). The first successful melanoma therapeutic has been BRAFV600E inhibitor therapy 
but that only targets 40% of melanoma patients and most patients eventually relapse (3). To 
combat the relapse to targeted therapy, combination of BRAFV600E and MEK inhibitors have 
seen higher responses but only extend the progression free survival about 4 months (4). 
Another therapeutic for melanoma is anti-CTLA4 immunotherapy. It can be administered to all 
melanoma patients but it only has a 10% response rate (5). Improved immunotherapy has been 
developed recently and response rates have improved to 40% with anti-PD1 immunotherapy 
(6). The complexity of treating melanoma patients is due to the diverse array of acquired and 
intrinsic resistance mechanisms to therapy which present huge challenges in generating long 
term remissions in patients (7, 8). Although great strides have been made in deciphering 
melanoma heterogeneity and uncovering resistance mechanisms to therapy, there still remains 
much to be discovered. It seems targeting one subpopulation is not enough for effective 
therapy, thus, characterization of melanoma subpopulations, and in particularly the signaling 
events that regulate phenotypic heterogeneity, might lead to the development of combination 
therapies targeting multiple subpopulations of tumor cells.  
Phenotypic heterogeneity in an individual melanoma tumor could arise from a variety of 
mechanisms including, epigenetic or genetic mutations, micro-environmental pressures, and 
reversible gene expression patterns. Our group has proposed phenotype switching as a 
mechanism for melanoma heterogeneity (9-11). The phenotype switching model defines two 
subpopulations of melanoma cells, the proliferative phenotype and the invasive phenotype. The 
proliferative phenotype is defined by expression of melanocytic markers like MITF, SOX10, and 
TYR and is characterized by a high proliferation rate and low invasion rate. The invasive 
phenotype is defined by expression of mesenchymal markers like WNT5A, TGFB, and SOX9 
and is characterized by a low proliferation rate and high invasion rate. In Chapter 5, we applied 
our phenotype gene signatures across all available melanoma microarray data in the GEO 
database. We first used a training set of 192 melanoma cell cultures and lines to define the 97 
gene signature that characterizes the proliferative and invasive phenotype. We tested this gene 
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signature on a test set of 318 melanoma cell cultures and lines and 81% of the samples have 
correlation to the proliferative or invasive gene signature. The two phenotypes are independent 
of mutation status, which suggests these phenotypes are driven by cell signaling. We also 
validate the phenotype of a few external melanoma cell cultures with in vitro experiments for 
proliferation and invasion. The results from this study demonstrate that melanoma cell 
phenotype is dictated by gene expression irrespective of genetic background.  
One gene of interest from the proliferative gene signature is SOX10. SOX10 is one of the 
essential genes involved in neural crest specification, differentiation and survival (12). SOX10 is 
critical for NCSC self-renewal and survival (13) and SOX10 mutation in mice causes a 
Dominant megacolon (Dom) phenotype (14). The Dom mice are characterized with aganglionic 
megacolon, deafness and hypopigmentation. In humans, SOX10 mutations cause Waardenburg 
Hirschsprung syndrome which share the same phenotype as the Dom mice (15). The 
hypopigmentation defect was the first indication that SOX10 plays a role in dictating the 
melanocytic lineage in NCSCs. SOX10 was later found to bind and activate the promoter of 
MITF, the master regulator of melanocytes (16). MITF is a transcription factor essential for 
melanocyte function, which activates a wide array of genes involved in cell-cycle progression 
(i.e. CDK2, p16) and melanocyte differentiation (i.e. TYR, MLANA) (reviewed in (17)). MITF was 
found to be amplified in 10-20% of melanoma (18) and expression of MITF was highly variable 
across melanoma specimens with the majority of primary melanomas having high MITF 
expression and a large percentage of metastatic melanomas with low MITF expression (19). 
SOX10 is also essential for normal melanocyte function and melanoma formation (20-23). In the 
Tyr::NrasQ61K Ink4a-/- mouse model, melanoma tumors form spontaneously and are reflective of 
human melanoma, where 20% of patients have an NRAS mutation and often have p16 silenced 
(24). SOX10 haploinsufficiency in the Tyr::NrasQ61K Ink4a-/- mice rescues the mice from 
developing melanoma tumors and the mice have a normal pigmentation pattern. This suggests 
that in an oncogenic environment, lower levels of SOX10 prevents melanoma initiation and still 
allows for normal melanocyte function. High levels of SOX10 were found to be a poor prognostic 
marker for melanoma patients (25, 26). These findings highlight the importance of cell lineage 
developmental pathways in oncogenesis and perhaps targeting SOX10 in melanoma could be a 
potential therapeutic target.  
From the microarray data in Shakhova et al. shRNA knockdown of SOX10 elevates SOX9 
expression (22). SOX9, like SOX10, belongs in the SOXE family of transcription factors and can 
play redundant roles in the neural crest (27, 28). The primary role of SOX9 is in gonad and 
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chondrocyte development and loss of SOX9 does not affect the melanocytic lineage (29-31). 
Interestingly, ectopic expression of SOX9 under the DCT promoter affects melanoblast 
development, where the mouse has light coat pigmentation, dorsal white spotting and 
microphthalmia (32). Taken together, this could suggest that SOX9 has an antagonistic role to 
SOX10 in melanocyte and melanoma function. In Chapter 6, we investigated the role of SOX9 
on SOX10 in the context of melanoma formation. SOX9 and SOX10 mRNA and protein levels 
had an anti-correlative relationship in melanocytes, naevi, and melanoma and SOX9 binds to 
the promoter of SOX10. Overexpression of SOX9 decreased SOX10 levels and caused the 
melanoma cells to enter G1 cell cycle arrest.  Using Tyr::NrasQ61K Sox10fl/- and Tyr::NrasQ61K 
Sox10fl/fl mice, homozygous deletion of SOX9 restored the hyperpigmentation phenotype as 
originally seen in Tyr::NrasQ61K mice, suggesting that the effects of SOX10 loss are due to SOX9 
expression. Finally, looking at The Cancer Genome Atlas (TCGA) melanoma database, patients 
with high levels of SOX10 had poor prognosis compared to patients with low SOX10. These 
results indicate the importance of SOX9 in melanoma initiation suggesting it could play a 
potential tumor suppressor role by inhibiting SOX10. In terms of phenotype switching, the 
antagonistic role of SOX10 and SOX9 would fit the model, where SOX10 would be part of the 
proliferative phenotype and SOX9 would be part of the invasive phenotype. High SOX10 levels 
in mice caused increased proliferation of melanocytes which led to melanoma formation and 
suppression of SOX10 by SOX9 reduced tumor burden. The phenotype switching model 
predicts that high SOX9 levels would lead to increased invasion, but this was not addressed in 
this study. We investigate the invasive role of SOX9 in melanoma in Chapter 7. 
In addition to reversible gene expression as a contributor to melanoma heterogeneity, 
epigenetic mechanisms are also reversible and heritable. Thus epigenetic mechanisms can 
provide a stable mechanism for a cell to maintain a certain phenotype but also allow the cell to 
transition to another phenotype. DNA methylation is an epigenetic mechanism that is aberrantly 
expressed in cancer (33). As the genes in the proliferative and invasive phenotype are stably 
expressed, it is plausible that some of the genes are regulated by DNA methylation. To date, 
more than 70 genes have been found to be hyper-methylated in melanoma compared to normal 
melanocytes (reviewed in (34)). These genes encompass several important signaling pathways 
including MAPK, PI3K, and WNT and pathways involving cell cycle, apoptosis, and DNA repair. 
The majority of studies investigating the landscape of DNA methylation in melanoma compare 
melanoma to normal skin or to benign nevi (35-38). In Chapter 7, we investigate the DNA 
methylation landscape within melanoma, comparing the proliferative phenotype to the invasive 
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phenotype. Taking five proliferative phenotype cell cultures and five invasive phenotype cell 
cultures, we compared the DNA methylation profile and gene expression profile and found a 
number of genes that had anti-correlative DNA methylation and gene expression between the 
two phenotypes. One of the genes validated was SOX9. From Chapter 6, we know that 
overexpression of SOX9 suppresses the expression of SOX10 and causes the cells to enter G1 
cell cycle arrest. Invasive phenotype melanoma cell that endogenously express SOX9 have low 
levels of SOX10 and have a decreased proliferation capacity but are not arrested. It could be an 
artifact of overexpression that causes the cells to enter cell cycle arrest. The role of SOX9 in 
invasion was addressed with in vitro Boyden chamber assays on SOX9 knockdown and SOX9 
overexpression and in vivo metastasis assays with SOX9 overexpression in B16F1 cells. SOX9 
knockdown decreased the invasive capacity of the melanoma cells and SOX9 overexpression 
increased the invasive capacity of the melanoma cells. In vivo, B16F1 cells are not known to 
metastasize to the lung in a tail vein injection assay, but with SOX9 overexpression, melanoma 
nodules were detected in the lung. We also addressed the role of SOX9 in survival and 
discovered that patients with high SOX9 expression have poor prognosis compared to patients 
with low SOX9 expression in the TCGA melanoma dataset. Taken together, this study 
demonstrates that SOX9 is regulated by DNA methylation and its role in melanoma is to induce 
melanoma cell invasion which leads to poor prognosis for the patient. This would suggest that 
targeting the invasive phenotype cells perhaps through SOX9 would be beneficial for the 
patient.  
Interestingly, invasive phenotype cells are more resistant to targeted inhibitor therapy, 
suggesting it as an intrinsic resistance mechanism. Studies from Konieczkowski et al. and 
Zipser et al. both demonstrated that melanoma cells with low MITF expression were less 
sensitive to BRAF and MEK inhibitors and these drug resistant melanoma cells expressed high 
levels of NF-kB, AXL, WNT5A and TGFB (39, 40). These findings have potential implications for 
patient stratification in therapy treatment, as patients could be pre-screened for these invasive 
marker genes to determine the benefit of a targeted therapy. One possible avenue to combat 
intrinsic resistance is to target the invasive phenotype. Indeed a recent study demonstrated that 
methotrexate could push invasive phenotype cells toward the proliferative phenotype, thus 
sensitizing them to a TYR-processed antifolate prodrug (41). The ineffective results from single 
inhibitor treatment indicate that melanoma heterogeneity should be addressed when 
considering therapeutic targets, which suggests targeting multiple subpopulations might be 
more beneficial for the patient. Indeed, the current trend for melanoma therapy is combination 
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therapy; current strategies include inhibition of multiple targets of the same pathway, i.e. BRAF 
and MEK inhibitor combination treatment, or inhibition of parallel pathways, i.e. BRAF and PI3K 
inhibitor combination treatment (42, 43), but inhibitors targeting phenotype switching have not 
been introduced in human clinical trials yet.   
In this thesis, we suggest that targeting SOX10 and SOX9 could be beneficial for patient 
survival, as high levels of SOX10 expression are required for melanoma formation and high 
levels of SOX9 expression are required for melanoma invasion.  Survival analysis of patients 
with high expression of SOX10 or high expression of SOX9 both have poorer prognosis. This 
indicates that either phenotype for the patient is detrimental to their survival. The proliferative 
phenotype could cause increased tumor size and the invasive phenotype could cause more 
metastasis.  We show the dynamic nature of phenotype switching from the antagonistic 
relationship of SOX10 and SOX9 (Figure 1). Expression of SOX9 causes down regulation of 
SOX10 and vice versa. It would suggest that only targeting one phenotype leads to the 
expression of the other. For effective therapy, we would propose targeting both phenotypes. 
Transcription factors are difficult targets for current therapeutics thus elucidating downstream 
effector molecules for SOX10 and SOX9 would be crucial for drug design. The promising results 
from Saez-Ayala M et al. on combination therapy targeting both the proliferative and invasive 
phenotype with the TYR-processed antifolate prodrug and methotrexate in mice provide an 
encouraging rationale for developing more drugs that inhibit both phenotypes. Another potential 
target for therapy is targeting phenotype switching itself. Since the DNA methylation landscape 
is unique for the proliferative and invasive phenotype, utilizing a DNMT inhibitor like Azacytidine 
in combination with current therapies which could prevent the melanoma cells from switching 
phenotypes and developing resistance.   
In conclusion, the phenotype switching model provides a model for melanoma progression 
where melanoma cells transition between states of proliferation and invasion. In Chapter 5, we 
provided evidence that these phenotypes exist within melanoma cell cultures used worldwide. In 
Chapter 6, we demonstrate that SOX9 is a negative regulator of SOX10 in melanocytes and 
melanoma. In Chapter 7, we demonstrate that SOX9 is regulated by DNA methylation and is a 
negative prognostic factor for melanoma patients. All these data contribute to a growing field of 
phenotype switching in melanoma.  
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Figure 1. Phenotype Switching Model with SOX10 and SOX9. SOX10 expressing cells are proliferative 
and cause growth of the tumor. Downregulation of SOX10 leads to expression of SOX9. SOX9 
expressing cells are invasive and cause tumor invasion. Downregulation of SOX9 leads to expression of 
SOX10. Melanoma tumors are comprised of both SOX10 and SOX9 populations thus leading to growth 
and invasion of the tumors. 
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